TWI707030B - Chemical solution for forming water-repellent protective film and wafer surface treatment method - Google Patents

Chemical solution for forming water-repellent protective film and wafer surface treatment method Download PDF

Info

Publication number
TWI707030B
TWI707030B TW108101088A TW108101088A TWI707030B TW I707030 B TWI707030 B TW I707030B TW 108101088 A TW108101088 A TW 108101088A TW 108101088 A TW108101088 A TW 108101088A TW I707030 B TWI707030 B TW I707030B
Authority
TW
Taiwan
Prior art keywords
water
protective film
iii
chemical solution
wafer
Prior art date
Application number
TW108101088A
Other languages
Chinese (zh)
Other versions
TW201932575A (en
Inventor
福井由季
照井貴陽
山田周平
奧村雄三
公文創一
塩田彩織
近藤克哉
Original Assignee
日商中央硝子股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中央硝子股份有限公司 filed Critical 日商中央硝子股份有限公司
Publication of TW201932575A publication Critical patent/TW201932575A/en
Application granted granted Critical
Publication of TWI707030B publication Critical patent/TWI707030B/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/18Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/16Antifouling paints; Underwater paints
    • C09D5/1606Antifouling paints; Underwater paints characterised by the anti-fouling agent
    • C09D5/1612Non-macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/20Diluents or solvents
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/40Additives
    • C09D7/60Additives non-macromolecular
    • C09D7/63Additives non-macromolecular organic
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01LSEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/02041Cleaning
    • H01L21/02057Cleaning during device manufacture
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01LSEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/18Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic Table or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/30Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
    • H01L21/302Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to change their surface-physical characteristics or shape, e.g. etching, polishing, cutting
    • H01L21/306Chemical or electrical treatment, e.g. electrolytic etching

Landscapes

  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Materials Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Cleaning Or Drying Semiconductors (AREA)

Abstract

本發明提供一種可進一步提高撥水性賦予效果之撥水性保護膜形成用藥液。本發明之撥水性保護膜形成用藥液具有 (I)下述通式[1]所表示之胺基矽烷化合物、 (II)下述通式[2]所表示之矽化合物、及 (III)非質子性溶劑,且 相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%。

Figure 108101088-A0101-11-0001-1
The present invention provides a chemical liquid for forming a water-repellent protective film that can further improve the effect of imparting water-repellency. The chemical solution for forming a water-repellent protective film of the present invention has (I) an aminosilane compound represented by the following general formula [1], (II) a silicon compound represented by the following general formula [2], and (III) Protic solvent, and the content of (I) relative to the total amount of (I) to (III) is 0.02 to 0.5% by mass.
Figure 108101088-A0101-11-0001-1

Description

撥水性保護膜形成用藥液及晶圓之表面處理方法Chemical solution for forming water-repellent protective film and wafer surface treatment method

本發明係關於一種用以於基板(晶圓)表面之微細之凹凸圖案之凹部表面形成撥水性保護膜之撥水性保護膜形成用藥液及晶圓之表面處理方法。The present invention relates to a water-repellent protective film forming chemical solution for forming a water-repellent protective film on the surface of a fine concave-convex pattern on the surface of a substrate (wafer) and a surface treatment method for wafers.

對於網路或數位家電用之半導體元件,要求進一步之高性能、高功能化或低耗電化。因此,電路圖案之微細化得到推進,且伴隨半導體元件之微細化之圖案縱橫比變高之問題顯現。即,洗淨或沖洗後,於氣液界面通過圖案時引起圖案崩塌之現象(以下有時記載為「圖案崩塌」),良率大幅降低,該情況成為嚴重問題。For semiconductor devices used in networks or digital home appliances, further high performance, high functionality, or low power consumption are required. Therefore, the miniaturization of circuit patterns has been advanced, and the problem of the pattern aspect ratio becoming higher with the miniaturization of semiconductor devices has emerged. That is, after washing or rinsing, the phenomenon of pattern collapse (hereinafter sometimes referred to as "pattern collapse") when passing through the pattern at the gas-liquid interface, the yield rate is greatly reduced, and this situation becomes a serious problem.

該圖案崩塌係於自晶圓表面將洗淨液或沖洗液乾燥去除時產生。認為其原因在於,於圖案之縱橫比較高之部分及較低之部分之間,出現殘液高度之差異,由此,作用於圖案之毛細管力產生差異。因此,若藉由將洗淨液或沖洗液替換為撥水性保護膜形成用藥液於圖案表面形成撥水性保護膜,而減小作用於該圖案之毛細管力,則可期待殘液高度之不同所致之毛細管力之差異減小,圖案崩塌消除。The pattern collapse occurs when the cleaning solution or the rinse solution is dried and removed from the wafer surface. It is believed that the reason is that there is a difference in the height of the residual liquid between the part with a high aspect ratio and a low part of the pattern, and thus the capillary force acting on the pattern is different. Therefore, if the water-repellent protective film is formed on the pattern surface by replacing the cleaning liquid or rinsing liquid with the chemical liquid for forming a water-repellent protective film, and the capillary force acting on the pattern is reduced, the difference in the height of the residual liquid can be expected. The resulting difference in capillary force is reduced, and pattern collapse is eliminated.

本申請人於專利文獻1中揭示有一種撥水性保護膜形成用藥液、或使用該藥液之晶圓之洗淨方法,該藥液係用以於洗淨表面具有微細之凹凸圖案且該凹凸圖案之至少一部分包含矽元素之晶圓時,於該凹凸圖案之至少凹部表面形成撥水性保護膜,其特徵在於: 包含下述通式所表示之酸性矽化合物A及酸A, 該酸A係選自由三氟乙酸三甲基矽烷酯、三氟甲磺酸三甲基矽烷酯、三氟乙酸二甲基矽烷酯、三氟甲磺酸二甲基矽烷酯、三氟乙酸丁基二甲基矽烷酯、三氟甲磺酸丁基二甲基矽烷酯、三氟乙酸己基二甲基矽烷酯、三氟甲磺酸己基二甲基矽烷酯、三氟乙酸辛基二甲基矽烷酯、三氟甲磺酸辛基二甲基矽烷酯、三氟乙酸癸基二甲基矽烷酯、及三氟甲磺酸癸基二甲基矽烷酯所組成之群中之至少1種,且 上述藥液之起始原料中之水分之總量相對於該原料之總量為100質量ppm以下。 [化1]

Figure 02_image005
(R分別相互獨立地為選自包含碳數為1~18之烴基之1價有機基、及包含碳數為1~8之氟烷基鏈之1價有機基中之至少1種基,X分別相互獨立地為鍵結於Si元素之元素為氮之1價有機基,a係1~3之整數,b係0~2之整數,且a與b合計為1~3)。 先前技術文獻 專利文獻The applicant disclosed in Patent Document 1 a chemical solution for forming a water-repellent protective film or a method for cleaning a wafer using the chemical solution. The chemical solution is used to clean the surface with fine uneven patterns and the unevenness When at least a part of the pattern contains silicon on the wafer, a water-repellent protective film is formed on the surface of at least the concave portion of the concave-convex pattern, characterized in that it contains an acidic silicon compound A and an acid A represented by the following general formula. The acid A is Selected from trimethylsilyl trifluoroacetate, trimethylsilyl trifluoromethanesulfonate, dimethylsilyl trifluoroacetate, dimethylsilyl trifluoromethanesulfonate, butyldimethyl trifluoroacetate Silane ester, butyl dimethyl silyl trifluoromethanesulfonate, hexyl dimethyl silyl trifluoroacetate, hexyl dimethyl silyl trifluoromethanesulfonate, octyl dimethyl silyl trifluoroacetate, three At least one of the group consisting of octyl dimethyl silyl fluoromethanesulfonate, decyl dimethyl silyl trifluoroacetate, and decyl dimethyl silyl trifluoromethanesulfonate, and one of the above-mentioned liquids The total amount of moisture in the starting material is 100 mass ppm or less relative to the total amount of the material. [化1]
Figure 02_image005
(R is each independently at least one group selected from a monovalent organic group containing a hydrocarbon group with 1 to 18 carbons and a monovalent organic group containing a fluoroalkyl chain with 1 to 8 carbons, X Each independently of each other is a monovalent organic group in which the element bonded to the Si element is nitrogen, a is an integer of 1 to 3, b is an integer of 0 to 2, and the total of a and b is 1 to 3). Prior Art Document Patent Document

專利文獻1:日本專利第5821844號公報Patent Document 1: Japanese Patent No. 5821844

[發明所欲解決之問題][The problem to be solved by the invention]

於半導體元件製造中,尤其是目的在於提高微細且縱橫比較高之電路圖案化之元件之製造良率的基板(晶圓)之洗淨技術中,開發有撥水性保護膜形成用藥液。專利文獻1所記載之保護膜形成用藥液確實地發揮優異之撥水性賦予效果,並且藥液之起始原料中之水分之總量相對於該原料之總量為100質量ppm以下,由此藥液之保管穩定性優異。然而,近年來,半導體元件之高積體化、微小化之傾向提高,晶圓圖案之微細化、高縱橫比化不斷推進,故而對於減少圖案崩塌之撥水性保護膜形成用藥液期待撥水性賦予效果之進一步之提昇。 [解決問題之技術手段]In the manufacturing of semiconductor devices, especially in the cleaning technology of substrates (wafers) aimed at improving the manufacturing yield of circuit patterned devices with fine and high aspect ratios, a chemical solution for forming a water-repellent protective film has been developed. The chemical solution for forming a protective film described in Patent Document 1 reliably exerts an excellent water repellency imparting effect, and the total amount of water in the starting material of the chemical solution is 100 mass ppm or less relative to the total amount of the material. The storage stability of the liquid is excellent. However, in recent years, the trend toward higher integration and miniaturization of semiconductor devices has increased, and the miniaturization and high aspect ratio of wafer patterns have been advancing. Therefore, water-repellent protective film formation chemicals that reduce pattern collapse are expected to impart water-repellency The effect is further improved. [Technical means to solve the problem]

本發明係一種撥水性保護膜形成用藥液(以下,有時僅記載為「保護膜形成用藥液」或「藥液」),其具有 (I)下述通式[1]所表示之胺基矽烷化合物、 (II)下述通式[2]所表示之矽化合物、及 (III)非質子性溶劑,且 相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%。 [化2]

Figure 02_image007
[式[1]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;a係1~3之整數,b係0~2之整數,且a與b合計為1~3]。 [化3]
Figure 02_image009
[式[2]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;又,X表示選自由鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 所組成之群中之至少1種基;R3 係碳數為1至6之1價全氟烷基,c係1~3之整數,d係0~2之整數,且c與d合計為1~3]。The present invention is a chemical solution for forming a water-repellent protective film (hereinafter, sometimes only referred to as "a chemical solution for forming a protective film" or "a chemical solution"), which has (I) an amine group represented by the following general formula [1] Silane compound, (II) silicon compound represented by the following general formula [2], and (III) aprotic solvent, and the content of (I) relative to the total amount of (I) to (III) is 0.02~ 0.5% by mass. [化2]
Figure 02_image007
[In formula [1], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; a is an integer of 1 to 3, b is an integer of 0-2, and the total of a and b is 1-3]. [化3]
Figure 02_image009
[In formula [2], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with a carbon number of 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; and X represents selected from halogen groups , -OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C(S(=O) 2 -R 3 ) 3 At least one group in the group; R 3 is a monovalent perfluoroalkyl group with carbon number of 1 to 6, c is an integer of 1 to 3, d is an integer of 0 to 2, and the sum of c and d is 1~3].

又,若上述(I)為下述通式[3]所表示之化合物,則可均質地形成上述保護膜,故而更佳。 [化4]

Figure 02_image011
[式[3]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。In addition, if the above-mentioned (I) is a compound represented by the following general formula [3], the above-mentioned protective film can be formed homogeneously, which is more preferable. [化4]
Figure 02_image011
[In formula [3], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].

就製備藥液之容易度之觀點而言,上述藥液較佳為進而含有(IV)下述通式[4]所表示之矽氮烷化合物。 [化5]

Figure 02_image013
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。From the viewpoint of the ease of preparing the drug solution, the drug solution preferably further contains (IV) the silazane compound represented by the following general formula [4]. [化5]
Figure 02_image013
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].

又,關於相對於上述(I)~(III)之總量之(II)之含量,就提高撥水性賦予效果之觀點而言較佳為0.05質量%以上,又,就成本之觀點而言較佳為20質量%以下。In addition, the content of (II) relative to the total amount of (I) to (III) above is preferably 0.05% by mass or more from the viewpoint of improving the effect of imparting water repellency, and it is higher from the viewpoint of cost. Preferably, it is 20% by mass or less.

又,就提高撥水性賦予效果之觀點而言,上述(II)較佳為選自由下述通式[5]所組成之群中之至少1種化合物。 [化6]

Figure 02_image015
[式[5]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基,R3 係碳數為1至6之1價全氟烷基;又,g係1~3之整數]。In addition, from the viewpoint of improving the water repellency imparting effect, the above (II) is preferably at least one compound selected from the group consisting of the following general formula [5]. [化6]
Figure 02_image015
[In formula [5], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with a carbon number of 1 to 18 that can be substituted with a part or all of hydrogen elements and fluorine elements, and R 3 is a monovalent organic group with a carbon number of 1 to 6 is a monovalent perfluoroalkyl group; and, g is an integer of 1 to 3].

又,本發明係一種晶圓之表面處理方法,其具有撥水性保護膜形成步驟、及乾燥步驟,該撥水性保護膜形成步驟係於晶圓表面保持有選自由洗淨液及沖洗液所組成之群中之至少1種液體之狀態下,將該液體替換為撥水性保護膜形成用藥液且將該藥液保持於晶圓表面, 上述撥水性保護膜形成用藥液具有 (I)下述通式[1]所表示之胺基矽烷化合物、 (II)下述通式[2]所表示之矽化合物、及 (III)非質子性溶劑,且 相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%。 [化7]

Figure 02_image017
[式[1]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;a係1~3之整數,b係0~2之整數,且a與b合計為1~3]。 [化8]
Figure 02_image019
[式[2]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;又,X表示選自由鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 所組成之群中之至少1種基;R3 係碳數為1至6之1價全氟烷基,c係1~3之整數,d係0~2之整數,且c與d合計為1~3]。In addition, the present invention is a wafer surface treatment method, which has a water-repellent protective film forming step and a drying step. The water-repellent protective film forming step is composed of a cleaning solution and a rinsing solution on the wafer surface. In the state of at least one liquid in the group, the liquid is replaced with a chemical solution for forming a water-repellent protective film and the chemical solution is held on the surface of the wafer. The chemical solution for forming a water-repellent protective film has the following characteristics (I) The aminosilane compound represented by formula [1], (II) the silicon compound represented by the following general formula [2], and (III) aprotic solvent, relative to the total amount of (I) to (III) The content of (I) is 0.02 to 0.5 mass%. [化7]
Figure 02_image017
[In formula [1], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; a is an integer of 1 to 3, b is an integer of 0-2, and the total of a and b is 1-3]. [化8]
Figure 02_image019
[In formula [2], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with a carbon number of 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; and X represents selected from halogen groups , -OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C(S(=O) 2 -R 3 ) 3 At least one group in the group; R 3 is a monovalent perfluoroalkyl group with carbon number of 1 to 6, c is an integer of 1 to 3, d is an integer of 0 to 2, and the sum of c and d is 1~3].

又,若上述(I)為下述通式[3]所表示之化合物,則可均質地形成上述保護膜,故而更佳。 [化9]

Figure 02_image021
[式[3]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。In addition, if the above-mentioned (I) is a compound represented by the following general formula [3], the above-mentioned protective film can be formed homogeneously, which is more preferable. [化9]
Figure 02_image021
[In formula [3], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].

上述方法中,就製備藥液之容易度之觀點而言,上述撥水性保護膜形成用藥液較佳為進而含有(IV)下述通式[4]所表示之矽氮烷化合物。 [化10]

Figure 02_image023
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。In the above method, from the viewpoint of the ease of preparing a chemical solution, the chemical solution for forming a water-repellent protective film preferably further contains (IV) a silazane compound represented by the following general formula [4]. [化10]
Figure 02_image023
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].

又,就製備藥液之容易度之觀點而言,上述方法較佳為於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使質子性化合物與具有 (II)上述通式[2]所表示之矽化合物、 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(III)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液。 [化11]

Figure 02_image025
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。In addition, from the viewpoint of the ease of preparing the drug solution, the above method preferably includes a drug solution preparation step before the water-repellent protective film formation step, and the drug solution preparation step is to make the protic compound and the (II) above The silicon compound represented by the general formula [2], (IV) the silazane compound represented by the following general formula [4], and (III) the crude drug solution of the aprotic solvent are compared to (II), (III) The total amount of 1 kg of) and (IV) is contacted at a ratio of 0.001 to 0.3 mol, thereby preparing (I) having the above (I) to (III) and relative to the total amount of (I) to (III) The content is 0.02-0.5% by mass of the water-repellent protective film forming liquid. [化11]
Figure 02_image025
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].

又,就製備藥液之容易度之觀點而言,上述方法較佳為於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使質子性化合物與具有 (II)上述通式[2]所表示之矽化合物、 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液。 [化12]

Figure 02_image027
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。In addition, from the viewpoint of the ease of preparing the drug solution, the above method preferably includes a drug solution preparation step before the water-repellent protective film formation step, and the drug solution preparation step is to make the protic compound and the (II) above The silicon compound represented by the general formula [2], (IV) the silazane compound represented by the following general formula [4], and (III) the crude drug solution of the aprotic solvent are compared to (II), (III) The total amount of 1 kg of ), (IV) is contacted at a ratio of 0.001 to 0.3 mol, thereby preparing (I) having the above (I) to (IV) and relative to the total amount of (I) to (III) The content is 0.02-0.5% by mass of the water-repellent protective film forming liquid. [化12]
Figure 02_image027
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].

又,上述方法中,上述藥液製備步驟若將上述原料藥液導入至含有質子性化合物之空間中而使兩者接觸,則容易使兩者均勻地接觸,故而較佳。再者,上述空間中所含有之質子性化合物可為液體狀態,亦可為氣體狀態。於質子性化合物為氣體狀態之情形時,較佳為管理空間中之質子性化合物之濃度(體積%)及接觸之時間。Furthermore, in the above method, it is preferable that the above-mentioned drug solution preparation step introduces the above-mentioned raw drug solution into the space containing the protic compound to bring the two into contact, so that the two can be brought into uniform contact easily. Furthermore, the protic compound contained in the aforementioned space may be in a liquid state or in a gas state. When the protic compound is in a gas state, it is better to manage the concentration (vol%) of the protic compound in the space and the contact time.

又,上述方法中,就提高撥水性賦予效果之觀點而言,上述質子性化合物較佳為具有-OH基、及/或-NH2 基之化合物,更佳為水、及/或、2-丙醇,尤佳為水。In the above method, from the viewpoint of improving the effect of imparting water repellency, the protic compound is preferably a compound having an -OH group and/or -NH 2 group, and more preferably water, and/or, 2- Propanol is particularly preferably water.

又,若上述方法於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使下述通式[6]所表示之酸性化合物與具有 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(III)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液,則可減少所使用之原料數量,因此就成本之觀點而言較佳。 [化13]

Figure 02_image029
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。 [化14]
Figure 02_image031
[式[6]中,X表示鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 ;且R3 係碳數為1至6之1價全氟烷基]。In addition, if the above method has a chemical solution preparation step before the water-repellent protective film formation step, the chemical solution preparation step is to combine the acidic compound represented by the following general formula [6] with the acid compound having (IV) the following general formula [4 ] The indicated silazane compound and (III) aprotic solvent raw material liquid are contacted at a ratio of 0.001 to 0.3 mol relative to the total amount of (III) and (IV) 1 kg, thereby preparing The water-repellent protective film forming chemical solution having the above (I) to (III) and the content of (I) relative to the total amount of (I) to (III) is 0.02 to 0.5% by mass, which can reduce the raw materials used Quantity, so it is better from a cost point of view. [化13]
Figure 02_image029
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3]. [化14]
Figure 02_image031
[In formula [6], X represents a halogen group, -OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C( S(=O) 2 -R 3 ) 3 ; and R 3 is a monovalent perfluoroalkyl group having 1 to 6 carbon atoms].

又,若上述方法於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使下述通式[6]所表示之酸性化合物與具有 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液,則可減少所使用之原料數量,就成本之觀點而言較佳。 [化15]

Figure 02_image033
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。 [化16]
Figure 02_image035
[式[6]中,X表示鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 ,且R3 係碳數為1至6之1價全氟烷基]。In addition, if the above method has a chemical solution preparation step before the water-repellent protective film formation step, the chemical solution preparation step is to combine the acidic compound represented by the following general formula [6] with the acid compound having (IV) the following general formula [4 ] The indicated silazane compound and (III) aprotic solvent raw material liquid are contacted at a ratio of 0.001 to 0.3 mol relative to the total amount of (III) and (IV) 1 kg, thereby preparing The water-repellent protective film forming chemical solution having the above (I) to (IV) and the content of (I) relative to the total amount of (I) to (III) is 0.02 to 0.5% by mass, which can reduce the raw materials used The quantity is better in terms of cost. [化15]
Figure 02_image033
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3]. [化16]
Figure 02_image035
[In formula [6], X represents a halogen group, -OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C( S(=O) 2 -R 3 ) 3 , and R 3 is a monovalent perfluoroalkyl group having 1 to 6 carbon atoms].

又,上述方法中,關於相對於上述(I)~(III)之總量之(II)之含量,就提高撥水性賦予效果之觀點而言較佳為0.05質量%以上,又,就成本之觀點而言較佳為20質量%以下。Furthermore, in the above method, the content of (II) relative to the total amount of (I) to (III) above is preferably 0.05% by mass or more from the viewpoint of improving the effect of imparting water repellency, and in terms of cost From a viewpoint, it is preferably 20% by mass or less.

又,上述方法中,若上述(II)係選自由下述通式[5]所組成之群中之至少1種化合物,則就提高撥水性賦予效果之觀點而言較佳。 [化17]

Figure 02_image037
[式[5]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基,R3 係碳數為1至6之1價全氟烷基;又,g係1~3之整數]。 [發明之效果]Moreover, in the above method, if the above (II) is at least one compound selected from the group consisting of the following general formula [5], it is preferable from the viewpoint of improving the water repellency imparting effect. [化17]
Figure 02_image037
[In formula [5], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with a carbon number of 1 to 18 that can be substituted with a part or all of hydrogen elements and fluorine elements, and R 3 is a monovalent organic group with a carbon number of 1 to 6 is a monovalent perfluoroalkyl group; and, g is an integer of 1 to 3]. [Effects of Invention]

根據本發明,提供一種可發揮更優異之撥水性賦予效果之新穎組成之撥水性保護膜形成用藥液、及使用該藥液之晶圓之表面處理方法。According to the present invention, there is provided a water-repellent protective film forming chemical solution with a novel composition that can exert a more excellent water-repellency imparting effect, and a surface treatment method of a wafer using the chemical solution.

1.撥水性保護膜形成用藥液 撥水性保護膜形成用藥液係於在被處理體之表面形成撥水性保護膜(以下,有時僅記載為「保護膜」)時使用。被處理體之種類並無特別限定。作為被處理體,較佳為「基板(晶圓)」。此處,作為成為處理對象之「晶圓」,例示用於製作半導體元件之晶圓,所謂「晶圓之表面」除晶圓本身之表面外,例示設置於晶圓上之無機圖案及樹脂圖案之表面、以及未經圖案化之無機層及有機層之表面。1. Chemical solution for forming water-repellent protective film The chemical solution for forming a water-repellent protective film is used when a water-repellent protective film (hereinafter, only referred to as "protective film") is formed on the surface of the object to be treated. The type of the object to be processed is not particularly limited. The object to be processed is preferably a "substrate (wafer)". Here, as the "wafer" to be processed, a wafer used for the production of semiconductor devices is exemplified. The so-called "surface of the wafer" exemplifies the inorganic pattern and resin pattern provided on the wafer in addition to the surface of the wafer itself. The surface of the inorganic layer and the surface of the organic layer without patterning.

作為設置於晶圓上之無機圖案,例示藉由光阻法於存在於晶圓之無機層之表面製作蝕刻遮罩,其後藉由蝕刻處理所形成之圖案。作為無機層,除晶圓本身外,例示構成晶圓之元素之氧化膜、形成於晶圓之表面之氮化矽、氮化鈦、鎢等無機物之膜或層等。此種膜或層並無特別限定,例示於半導體元件之製作過程中所形成之無機物之膜或層等。As the inorganic pattern provided on the wafer, an etching mask is made on the surface of the inorganic layer existing on the wafer by a photoresist method, and then a pattern formed by an etching process. As the inorganic layer, in addition to the wafer itself, an oxide film of the elements constituting the wafer, and a film or layer of inorganic substances such as silicon nitride, titanium nitride, and tungsten formed on the surface of the wafer are exemplified. Such a film or layer is not particularly limited, and is exemplified by an inorganic film or layer formed in the production process of a semiconductor element.

作為設置於晶圓上之樹脂圖案,例示藉由光阻法形成於晶圓上之樹脂圖案。此種樹脂圖案例如藉由以下方式形成,即,於晶圓上形成作為光阻膜之有機層,對該有機層通過光罩進行曝光而顯影。作為有機層,除晶圓本身之表面外,例示設置於晶圓之表面所設置之積層膜之表面等之有機層。此種有機層並無特別限定,例示於半導體元件之製作過程中為了形成蝕刻遮罩而設置之有機物之膜。As the resin pattern provided on the wafer, a resin pattern formed on the wafer by a photoresist method is exemplified. Such a resin pattern is formed, for example, by forming an organic layer as a photoresist film on a wafer, and exposing and developing the organic layer through a photomask. As the organic layer, in addition to the surface of the wafer itself, an organic layer such as the surface of a laminated film provided on the surface of the wafer is exemplified. The organic layer is not particularly limited, and is exemplified in a film of an organic substance provided to form an etching mask during the production process of a semiconductor device.

可藉由旋轉塗佈法或浸漬法等手段將預先製備而獲得之本發明之藥液塗佈於晶圓等被處理體之表面而使之保持於該表面。又,亦可使上述藥液蒸氣化並供給至晶圓等被處理體之表面(以下,有時記載為「蒸氣法」)而使之保持於該表面。The drug solution of the present invention prepared in advance can be applied to the surface of a processed object such as a wafer by means of a spin coating method or a dipping method, etc., so that it can be held on the surface. In addition, the above-mentioned chemical solution may be vaporized and supplied to the surface of the object to be processed such as a wafer (hereinafter, sometimes referred to as a "vapor method") to be held on the surface.

進而,亦可於藉由旋轉塗佈法、浸漬法或蒸氣法等手段將上述原料藥液塗佈於晶圓等被處理體之表面之狀態下使原料藥液與質子性化合物接觸而藉由後述反應製備撥水性保護膜形成用藥液,並使其保持於被處理體之表面。 又,亦可於預先含有質子性化合物之空間中,藉由旋轉塗佈法、浸漬法或蒸氣法等手段將上述原料藥液塗佈於晶圓等被處理體之表面而藉由後述反應製備撥水性保護膜形成用藥液,並使其保持於被處理體之表面。Furthermore, it is also possible to contact the raw chemical solution with the protic compound in a state where the raw chemical solution is applied to the surface of the object to be processed such as a wafer by means of spin coating, dipping, or steam. The chemical solution for forming a water-repellent protective film is prepared by the reaction described later, and is held on the surface of the object to be treated. In addition, in a space containing a protic compound in advance, the above-mentioned raw chemical solution may be applied to the surface of a processed object such as a wafer by means of spin coating, dipping, or steam, and prepared by the reaction described below. The water-repellent protective film is formed with a chemical solution, and it is kept on the surface of the object to be treated.

本發明之撥水性保護膜形成用藥液至少包含(I)胺基矽烷化合物、(II)矽化合物、及(III)非質子性溶劑。以下,對各成分進行說明。The chemical solution for forming a water-repellent protective film of the present invention contains at least (I) an aminosilane compound, (II) a silicon compound, and (III) an aprotic solvent. Hereinafter, each component will be described.

[(I)胺基矽烷化合物及(II)矽化合物] 上述通式[1]之R1 及上述通式[2]之R2 係撥水性之官能基。而且,例如於被處理體為含有矽之晶圓之情形時,上述通式[1]之-NH2 基或上述通式[2]之-X基與晶圓表面之矽烷醇基等進行反應,具有上述撥水性之官能基之部位固定於晶圓表面,藉此於該晶圓表面形成撥水性之保護膜。藉由使用上述(I)及(II)兩者,兩者快速地與晶圓表面進行反應,可獲得更優異之撥水性賦予效果。[(I) Aminosilane compound and (II) Silicon compound] R 1 of the general formula [1] and R 2 of the general formula [2] are water-repellent functional groups. And, for example, when the object to be processed is a wafer containing silicon, the -NH 2 group of the general formula [1] or the -X group of the general formula [2] reacts with the silanol group on the wafer surface , The part having the above water-repellent functional group is fixed on the surface of the wafer, thereby forming a water-repellent protective film on the surface of the wafer. By using both the above (I) and (II), both react quickly with the wafer surface, and a more excellent water repellency imparting effect can be obtained.

若上述通式[1]之R1 係直鏈狀烷基,則於作為上述被處理體之晶圓表面形成保護膜時,可對該表面賦予更優異之撥水性,故而較佳。If R 1 of the above general formula [1] is a linear alkyl group, when a protective film is formed on the surface of the wafer as the object to be processed, it can impart more excellent water repellency to the surface, which is preferable.

作為上述通式[1]所表示之胺基矽烷化合物之具體例,例如可列舉:CH3 Si(NH2 )3 、C2 H5 Si(NH2 )3 、C3 H7 Si(NH2 )3 、C4 H9 Si(NH2 )3 、C5 H11 Si(NH2 )3 、C6 H13 Si(NH2 )3 、C7 H15 Si(NH2 )3 、C8 H17 Si(NH2 )3 、C9 H19 Si(NH2 )3 、C10 H21 Si(NH2 )3 、C11 H23 Si(NH2 )3 、C12 H25 Si(NH2 )3 、C13 H27 Si(NH2 )3 、C14 H29 Si(NH2 )3 、C15 H31 Si(NH2 )3 、C16 H33 Si(NH2 )3 、C17 H35 Si(NH2 )3 、C18 H37 Si(NH2 )3 、(CH3 )2 Si(NH2 )2 、C2 H5 Si(CH3 )(NH2 )2 、(C2 H5 )2 Si(NH2 )2 、C3 H7 Si(CH3 )(NH2 )2 、(C3 H7 )2 Si(NH2 )2 、C4 H9 Si(CH3 )(NH2 )2 、(C4 H9 )2 Si(NH2 )2 、C5 H11 Si(CH3 )(NH2 )2 、C6 H13 Si(CH3 )(NH2 )2 、C7 H15 Si(CH3 )(NH2 )2 、C8 H17 Si(CH3 )(NH2 )2 、C9 H19 Si(CH3 )(NH2 )2 、C10 H21 Si(CH3 )(NH2 )2 、C11 H23 Si(CH3 )(NH2 )2 、C12 H25 Si(CH3 )(NH2 )2 、C13 H27 Si(CH3 )(NH2 )2 、C14 H29 Si(CH3 )(NH2 )2 、C15 H31 Si(CH3 )(NH2 )2 、C16 H33 Si(CH3 )(NH2 )2 、C17 H35 Si(CH3 )(NH2 )2 、C18 H37 Si(CH3 )(NH2 )2 、(CH3 )3 SiNH2 、C2 H5 Si(CH3 )2 NH2 、(C2 H5 )2 Si(CH3 )NH2 、(C2 H5 )3 SiNH2 、C3 H7 Si(CH3 )2 NH2 、(C3 H7 )2 Si(CH3 )NH2 、(C3 H7 )3 SiNH2 、C4 H9 Si(CH3 )2 NH2 、(C4 H9 )3 SiNH2 、C5 H11 Si(CH3 )2 NH2 、C6 H13 Si(CH3 )2 NH2 、C7 H15 Si(CH3 )2 NH2 、C8 H17 Si(CH3 )2 NH2 、C9 H19 Si(CH3 )2 NH2 、C10 H21 Si(CH3 )2 NH2 、C11 H23 Si(CH3 )2 NH2 、C12 H25 Si(CH3 )2 NH2 、C13 H27 Si(CH3 )2 NH2 、C14 H29 Si(CH3 )2 NH2 、C15 H31 Si(CH3 )2 NH2 、C16 H33 Si(CH3 )2 NH2 、C17 H35 Si(CH3 )2 NH2 、C18 H37 Si(CH3 )2 NH2 、(CH3 )2 Si(H)NH2 、CH3 Si(H)2 NH2 、(C2 H5 )2 Si(H)NH2 、C2 H5 Si(H)2 NH2 、C2 H5 Si(CH3 )(H)NH2 、(C3 H7 )2 Si(H)NH2 、C3 H7 Si(H)2 NH2 、CF3 CH2 CH2 Si(NH2 )3 、C2 F5 CH2 CH2 Si(NH2 )3 、C3 F7 CH2 CH2 Si(NH2 )3 、C4 F9 CH2 CH2 Si(NH2 )3 、C5 F11 CH2 CH2 Si(NH2 )3 、C6 F13 CH2 CH2 Si(NH2 )3 、C7 F15 CH2 CH2 Si(NH2 )3 、C8 F17 CH2 CH2 Si(NH2 )3 、CF3 CH2 CH2 Si(CH3 )(NH2 )2 、C2 F5 CH2 CH2 Si(CH3 )(NH2 )2 、C3 F7 CH2 CH2 Si(CH3 )(NH2 )2 、C4 F9 CH2 CH2 Si(CH3 )(NH2 )2 、C5 F11 CH2 CH2 Si(CH3 )(NH2 )2 、C6 F13 CH2 CH2 Si(CH3 )(NH2 )2 、C7 F15 CH2 CH2 Si(CH3 )(NH2 )2 、C8 F17 CH2 CH2 Si(CH3 )(NH2 )2 、CF3 CH2 CH2 Si(CH3 )2 NH2 、C2 F5 CH2 CH2 Si(CH3 )2 NH2 、C3 F7 CH2 CH2 Si(CH3 )2 NH2 、C4 F9 CH2 CH2 Si(CH3 )2 NH2 、C5 F11 CH2 CH2 Si(CH3 )2 NH2 、C6 F13 CH2 CH2 Si(CH3 )2 NH2 、C7 F15 CH2 CH2 Si(CH3 )2 NH2 、C8 F17 CH2 CH2 Si(CH3 )2 NH2 、CF3 CH2 CH2 Si(CH3 )(H)NH2 等。As specific examples of the aminosilane compound represented by the general formula [1], for example, CH 3 Si(NH 2 ) 3 , C 2 H 5 Si(NH 2 ) 3 , C 3 H 7 Si(NH 2 ) 3 , C 4 H 9 Si(NH 2 ) 3 , C 5 H 11 Si(NH 2 ) 3 , C 6 H 13 Si(NH 2 ) 3 , C 7 H 15 Si(NH 2 ) 3 , C 8 H 17 Si(NH 2 ) 3 , C 9 H 19 Si(NH 2 ) 3 , C 10 H 21 Si(NH 2 ) 3 , C 11 H 23 Si(NH 2 ) 3 , C 12 H 25 Si(NH 2 ) 3. C 13 H 27 Si(NH 2 ) 3 , C 14 H 29 Si(NH 2 ) 3 , C 15 H 31 Si(NH 2 ) 3 , C 16 H 33 Si(NH 2 ) 3 , C 17 H 35 Si(NH 2 ) 3 , C 18 H 37 Si(NH 2 ) 3 , (CH 3 ) 2 Si(NH 2 ) 2 , C 2 H 5 Si(CH 3 )(NH 2 ) 2 , (C 2 H 5 ) 2 Si(NH 2 ) 2 , C 3 H 7 Si(CH 3 )(NH 2 ) 2 , (C 3 H 7 ) 2 Si(NH 2 ) 2 , C 4 H 9 Si(CH 3 )(NH 2 ) 2 , (C 4 H 9 ) 2 Si(NH 2 ) 2 , C 5 H 11 Si(CH 3 )(NH 2 ) 2 , C 6 H 13 Si(CH 3 )(NH 2 ) 2 , C 7 H 15 Si(CH 3 )(NH 2 ) 2 , C 8 H 17 Si(CH 3 )(NH 2 ) 2 , C 9 H 19 Si(CH 3 )(NH 2 ) 2 , C 10 H 21 Si(CH 3 )(NH 2 ) 2 , C 11 H 23 Si(CH 3 )(NH 2 ) 2 , C 12 H 25 Si(CH 3 )(NH 2 ) 2 , C 13 H 27 Si(CH 3 )(NH 2 ) 2. C 14 H 29 Si(CH 3 )(NH 2 ) 2 , C 15 H 31 Si(CH 3 )(NH 2 ) 2 , C 16 H 33 Si(CH 3 )(NH 2 ) 2 , C 17 H 35 Si(CH 3 )(NH 2 ) 2 , C 18 H 37 Si(CH 3 )(NH 2 ) 2 , (CH 3 ) 3 SiNH 2 , C 2 H 5 Si(CH 3 ) 2 NH 2 , (C 2 H 5 ) 2 Si(CH 3 )NH 2 , (C 2 H 5 ) 3 SiNH 2 , C 3 H 7 Si(CH 3 ) 2 NH 2 , (C 3 H 7 ) 2 Si(CH 3 )NH 2 , (C 3 H 7 ) 3 SiNH 2 , C 4 H 9 Si(CH 3 ) 2 NH 2 , (C 4 H 9 ) 3 SiNH 2 , C 5 H 11 Si(CH 3 ) 2 NH 2 , C 6 H 13 Si(CH 3 ) 2 NH 2 , C 7 H 15 Si(CH 3 ) 2 NH 2 , C 8 H 17 Si(CH 3 ) 2 NH 2 , C 9 H 19 Si(CH 3 ) 2 NH 2 , C 10 H 21 Si(CH 3 ) 2 NH 2 , C 11 H 23 Si(CH 3 ) 2 NH 2 , C 12 H 25 Si(CH 3 ) 2 NH 2 , C 13 H 27 Si(CH 3 ) 2 NH 2 , C 14 H 29 Si(CH 3 ) 2 NH 2 , C 15 H 31 Si(CH 3 ) 2 NH 2 , C 16 H 33 Si(CH 3 ) 2 NH 2 , C 17 H 35 Si(CH 3 ) 2 NH 2 , C 18 H 37 Si(CH 3 ) 2 NH 2 , (CH 3 ) 2 Si(H)NH 2 , CH 3 Si(H) 2 NH 2 , (C 2 H 5 ) 2 Si(H)NH 2 , C 2 H 5 Si(H) 2 NH 2 , C 2 H 5 Si(CH 3 )(H)NH 2 , (C 3 H 7 ) 2 Si(H)NH 2 , C 3 H 7 Si(H) 2 NH 2 , CF 3 CH 2 CH 2 Si( NH 2 ) 3 , C 2 F 5 CH 2 CH 2 Si(NH 2 ) 3 , C 3 F 7 CH 2 CH 2 Si(NH 2 ) 3 , C 4 F 9 CH 2 CH 2 Si(NH 2 ) 3 , C 5 F 11 CH 2 CH 2 Si(NH 2 ) 3 , C 6 F 13 CH 2 CH 2 Si(NH 2 ) 3 , C 7 F 15 CH 2 CH 2 Si(NH 2 ) 3 , C 8 F 17 CH 2 CH 2 Si(NH 2 ) 3 , CF 3 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , C 2 F 5 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , C 3 F 7 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , C 4 F 9 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , C 5 F 11 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , C 6 F 13 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , C 7 F 15 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , C 8 F 17 CH 2 CH 2 Si(CH 3 )(NH 2 ) 2 , CF 3 CH 2 CH 2 Si(CH 3 ) 2 NH 2 , C 2 F 5 CH 2 CH 2 Si(CH 3 ) 2 NH 2 , C 3 F 7 CH 2 CH 2 Si(CH 3 ) 2 NH 2 , C 4 F 9 CH 2 CH 2 Si(CH 3 ) 2 NH 2 , C 5 F 11 CH 2 CH 2 Si(CH 3 ) 2 NH 2 , C 6 F 13 CH 2 CH 2 Si(CH 3 ) 2 NH 2 , C 7 F 15 CH 2 CH 2 Si(CH 3 ) 2 NH 2 , C 8 F 17 CH 2 CH 2 Si(CH 3 ) 2 NH 2. CF 3 CH 2 CH 2 Si(CH 3 )(H)NH 2 and so on.

又,若上述通式[1]中4-a-b所表示之-NH2 基之數量為1,則可均質地形成上述保護膜,故而更佳。In addition, if the number of -NH 2 groups represented by 4-ab in the general formula [1] is 1, the protective film can be uniformly formed, which is more preferable.

又,若上述通式[1]中b為0,則即便於進行後述保護膜形成後之洗淨(沖洗)之情形時,亦容易維持撥水性,故而較佳。In addition, if b in the above general formula [1] is 0, it is easier to maintain water repellency even when washing (rinsing) after formation of the protective film described later is performed, which is preferable.

進而,若上述R1 係2個-CH3 基與1個直鏈狀烷基之組合,則可均質地形成上述保護膜,故而更佳。進而,尤佳為上述R1 為3個-CH3 基。Furthermore, if the above-mentioned R 1 is a combination of two -CH 3 groups and one linear alkyl group, the above-mentioned protective film can be formed homogeneously, which is more preferable. Furthermore, it is particularly preferable that the above-mentioned R 1 is three -CH 3 groups.

又,上述通式[1]所表示之胺基矽烷化合物亦可為藉由反應所獲得者。In addition, the aminosilane compound represented by the general formula [1] may be obtained by reaction.

上述(I)胺基矽烷化合物相對於(I)~(III)之總量為0.02~0.5質量%。若未達0.02質量%,則無法達成撥水性賦予效果之進一步之提高。又,若超過0.5質量%,則胺基矽烷彼此容易發生反應,故而難以製備藥液。較佳為0.03~0.4質量%,更佳為0.03~0.3質量%。The (I) aminosilane compound is 0.02 to 0.5% by mass relative to the total amount of (I) to (III). If it is less than 0.02% by mass, further improvement of the water repellency imparting effect cannot be achieved. In addition, if it exceeds 0.5% by mass, aminosilanes are likely to react with each other, making it difficult to prepare a chemical solution. It is preferably 0.03 to 0.4% by mass, and more preferably 0.03 to 0.3% by mass.

又,作為上述通式[2]所表示之矽化合物之具體例,可列舉:CH3 Si(OC(=O)CF3 )3 、C2 H5 Si(OC(=O)CF3 )3 、C3 H7 Si(OC(=O)CF3 )3 、C4 H9 Si(OC(=O)CF3 )3 、C5 H11 Si(OC(=O)CF3 )3 、C6 H13 Si(OC(=O)CF3 )3 、C7 H15 Si(OC(=O)CF3 )3 、C8 H17 Si(OC(=O)CF3 )3 、C9 H19 Si(OC(=O)CF3 )3 、C10 H21 Si(OC(=O)CF3 )3 、C11 H23 Si(OC(=O)CF3 )3 、C12 H25 Si(OC(=O)CF3 )3 、C13 H27 Si(OC(=O)CF3 )3 、C14 H29 Si(OC(=O)CF3 )3 、C15 H31 Si(OC(=O)CF3 )3 、C16 H33 Si(OC(=O)CF3 )3 、C17 H35 Si(OC(=O)CF3 )3 、C18 H37 Si(OC(=O)CF3 )3 、(CH3 )2 Si(OC(=O)CF3 )2 、C2 H5 Si(CH3 )(OC(=O)CF3 )2 、(C2 H5 )2 Si(OC(=O)CF3 )2 、C3 H7 Si(CH3 )(OC(=O)CF3 )2 、(C3 H7 )2 Si(OC(=O)CF3 )2 、C4 H9 Si(CH3 )(OC(=O)CF3 )2 、(C4 H9 )2 Si(OC(=O)CF3 )2 、C5 H11 Si(CH3 )(OC(=O)CF3 )2 、C6 H13 Si(CH3 )(OC(=O)CF3 )2 、C7 H15 Si(CH3 )(OC(=O)CF3 )2 、C8 H17 Si(CH3 )(OC(=O)CF3 )2 、C9 H19 Si(CH3 )(OC(=O)CF3 )2 、C10 H21 Si(CH3 )(OC(=O)CF3 )2 、C11 H23 Si(CH3 )(OC(=O)CF3 )2 、C12 H25 Si(CH3 )(OC(=O)CF3 )2 、C13 H27 Si(CH3 )(OC(=O)CF3 )2 、C14 H29 Si(CH3 )(OC(=O)CF3 )2 、C15 H31 Si(CH3 )(OC(=O)CF3 )2 、C16 H33 Si(CH3 )(OC(=O)CF3 )2 、C17 H35 Si(CH3 )(OC(=O)CF3 )2 、C18 H37 Si(CH3 )(OC(=O)CF3 )2 、(CH3 )3 SiOC(=O)CF3 、C2 H5 Si(CH3 )2 OC(=O)CF3 、(C2 H5 )2 Si(CH3 )OC(=O)CF3 、(C2 H5 )3 SiOC(=O)CF3 、C3 H7 Si(CH3 )2 OC(=O)CF3 、(C3 H7 )2 Si(CH3 )OC(=O)CF3 、(C3 H7 )3 SiOC(=O)CF3 、C4 H9 Si(CH3 )2 OC(=O)CF3 、(C4 H9 )3 SiOC(=O)CF3 、C5 H11 Si(CH3 )2 OC(=O)CF3 、C6 H13 Si(CH3 )2 OC(=O)CF3 、C7 H15 Si(CH3 )2 OC(=O)CF3 、C8 H17 Si(CH3 )2 OC(=O)CF3 、C9 H19 Si(CH3 )2 OC(=O)CF3 、C10 H21 Si(CH3 )2 OC(=O)CF3 、C11 H23 Si(CH3 )2 OC(=O)CF3 、C12 H25 Si(CH3 )2 OC(=O)CF3 、C13 H27 Si(CH3 )2 OC(=O)CF3 、C14 H29 Si(CH3 )2 OC(=O)CF3 、C15 H31 Si(CH3 )2 OC(=O)CF3 、C16 H33 Si(CH3 )2 OC(=O)CF3 、C17 H35 Si(CH3 )2 OC(=O)CF3 、C18 H37 Si(CH3 )2 OC(=O)CF3 、(CH3 )2 Si(H)OC(=O)CF3 、CH3 Si(H)2 OC(=O)CF3 、(C2 H5 )2 Si(H)OC(=O)CF3 、C2 H5 Si(H)2 OC(=O)CF3 、C2 H5 Si(CH3 )(H)OC(=O)CF3 、(C3 H7 )2 Si(H)OC(=O)CF3 、C3 H7 Si(H)2 OC(=O)CF3 、CF3 CH2 CH2 Si(OC(=O)CF3 )3 、C2 F5 CH2 CH2 Si(OC(=O)CF3 )3 、C3 F7 CH2 CH2 Si(OC(=O)CF3 )3 、C4 F9 CH2 CH2 Si(OC(=O)CF3 )3 、C5 F11 CH2 CH2 Si(OC(=O)CF3 )3 、C6 F13 CH2 CH2 Si(OC(=O)CF3 )3 、C7 F15 CH2 CH2 Si(OC(=O)CF3 )3 、C8 F17 CH2 CH2 Si(OC(=O)CF3 )3 、CF3 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、C2 F5 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、C3 F7 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、C4 F9 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、C5 F11 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、C6 F13 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、C7 F15 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、C8 F17 CH2 CH2 Si(CH3 )(OC(=O)CF3 )2 、CF3 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、C2 F5 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、C3 F7 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、C4 F9 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、C5 F11 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、C6 F13 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、C7 F15 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、C8 F17 CH2 CH2 Si(CH3 )2 OC(=O)CF3 、CF3 CH2 CH2 Si(CH3 )(H)OC(=O)CF3 等三氟乙醯氧基矽烷、或將上述三氟乙醯氧基矽烷之-OC(=O)CF3 基替換為鹵基、-OC(=O)CF3 基以外之-OC(=O)R3 基、-OS(=O)2 -R3 基、-N(S(=O)2 -R3 )2 基、-C(S(=O)2 -R3 )3 基(R3 係碳數為1至6之1價全氟烷基)而成者等。In addition, as specific examples of the silicon compound represented by the general formula [2], CH 3 Si(OC(=O)CF 3 ) 3 , C 2 H 5 Si(OC(=O)CF 3 ) 3 , C 3 H 7 Si(OC(=O)CF 3 ) 3 , C 4 H 9 Si(OC(=O)CF 3 ) 3 , C 5 H 11 Si(OC(=O)CF 3 ) 3 , C 6 H 13 Si(OC(=O)CF 3 ) 3 , C 7 H 15 Si(OC(=O)CF 3 ) 3 , C 8 H 17 Si(OC(=O)CF 3 ) 3 , C 9 H 19 Si(OC(=O)CF 3 ) 3 , C 10 H 21 Si(OC(=O)CF 3 ) 3 , C 11 H 23 Si(OC(=O)CF 3 ) 3 , C 12 H 25 Si (OC(=O)CF 3 ) 3 , C 13 H 27 Si(OC(=O)CF 3 ) 3 , C 14 H 29 Si(OC(=O)CF 3 ) 3 , C 15 H 31 Si(OC (=O)CF 3 ) 3 , C 16 H 33 Si(OC(=O)CF 3 ) 3 , C 17 H 35 Si(OC(=O)CF 3 ) 3 , C 18 H 37 Si(OC(= O)CF 3 ) 3 , (CH 3 ) 2 Si(OC(=O)CF 3 ) 2 , C 2 H 5 Si(CH 3 )(OC(=O)CF 3 ) 2 , (C 2 H 5 ) 2 Si(OC(=O)CF 3 ) 2 , C 3 H 7 Si(CH 3 )(OC(=O)CF 3 ) 2 , (C 3 H 7 ) 2 Si(OC(=O)CF 3 ) 2. C 4 H 9 Si(CH 3 )(OC(=O)CF 3 ) 2 , (C 4 H 9 ) 2 Si(OC(=O)CF 3 ) 2 , C 5 H 11 Si(CH 3 ) (OC(=O)CF 3 ) 2 、C 6 H 13 Si(CH 3 )(OC(=O)CF 3 ) 2 、C 7 H 15 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 8 H 17 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 9 H 19 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 10 H 21 Si(CH 3 ) (OC(=O)CF 3 ) 2 、C 11 H 23 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 12 H 25 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 13 H 27 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 14 H 29 Si( CH 3 )(OC(=O)CF 3 ) 2 , C 15 H 31 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 16 H 33 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 17 H 35 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 18 H 37 Si(CH 3 )(OC(=O)CF 3 ) 2 , (CH 3 ) 3 SiOC (=O)CF 3 , C 2 H 5 Si(CH 3 ) 2 OC(=O)CF 3 , (C 2 H 5 ) 2 Si(CH 3 )OC(=O)CF 3 , (C 2 H 5 ) 3 SiOC(=O)CF 3 , C 3 H 7 Si(CH 3 ) 2 OC(=O)CF 3 , (C 3 H 7 ) 2 Si(CH 3 )OC(=O)CF 3 , (C 3 H 7 ) 3 SiOC(=O)CF 3 , C 4 H 9 Si(CH 3 ) 2 OC(=O)CF 3 , (C 4 H 9 ) 3 SiOC(=O)CF 3 , C 5 H 11 Si(CH 3 ) 2 OC(=O)CF 3 , C 6 H 13 Si(CH 3 ) 2 OC(=O)CF 3 , C 7 H 15 Si(CH 3 ) 2 OC(=O)CF 3 , C 8 H 17 Si(CH 3 ) 2 OC(=O)CF 3 , C 9 H 19 Si(CH 3 ) 2 OC(=O)CF 3 , C 10 H 21 Si(CH 3 ) 2 OC(=O )CF 3 , C 11 H 23 Si(CH 3 ) 2 OC(=O)CF 3 , C 12 H 25 Si(CH 3 ) 2 OC(=O)CF 3 , C 13 H 27 Si(CH 3 ) 2 OC(=O)CF 3 , C 14 H 29 Si(CH 3 ) 2 OC(=O)CF 3 , C 15 H 31 Si(CH 3 ) 2 OC(=O)CF 3 , C 16 H 33 Si( CH 3 ) 2 OC(=O)CF 3 , C 17 H 35 Si(CH 3 ) 2 OC(=O)CF 3 , C 18 H 37 Si(CH 3 ) 2 OC(=O)CF 3 , (CH 3 ) 2 Si(H)OC(=O)CF 3 , CH 3 Si(H) 2 OC(=O)CF 3 , (C 2 H 5 ) 2 Si(H)OC(=O)CF 3 , C 2 H 5 Si(H) 2 OC(=O)CF 3 , C 2 H 5 Si(CH 3 )(H)OC(=O)CF 3 , (C 3 H 7 ) 2 Si(H)OC (=O)CF 3 , C 3 H 7 Si(H) 2 OC(=O)CF 3 , CF 3 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , C 2 F 5 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , C 3 F 7 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , C 4 F 9 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , C 5 F 11 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , C 6 F 13 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , C 7 F 15 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , C 8 F 17 CH 2 CH 2 Si(OC(=O)CF 3 ) 3 , CF 3 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 2 F 5 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 3 F 7 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 4 F 9 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 5 F 11 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 6 F 13 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 7 F 15 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 , C 8 F 17 CH 2 CH 2 Si(CH 3 )(OC(=O)CF 3 ) 2 、CF 3 CH 2 CH 2 Si(CH 3 ) 2 OC(=O)CF 3 、C 2 F 5 CH 2 CH 2 Si(CH 3 ) 2 OC(=O)CF 3 , C 3 F 7 CH 2 CH 2 Si(CH 3 ) 2 OC(=O)CF 3 , C 4 F 9 CH 2 CH 2 Si(CH 3 ) 2 OC(=O)CF 3 , C 5 F 11 CH 2 CH 2 Si(CH 3 ) 2 OC(=O)CF 3 , C 6 F 13 CH 2 CH 2 Si(CH 3 ) 2 OC(=O) CF 3 , C 7 F 15 CH 2 CH 2 Si(CH 3 ) 2 OC(=O) CF 3 , C 8 F 17 CH 2 CH 2 Si(CH 3 ) 2 OC(=O) CF 3 , CF 3 CH 2 CH 2 Si(CH 3 )(H)OC(=O)CF 3 and other trifluoroacetoxysilane, or replace the -OC(=O)CF 3 group of the above trifluoroacetoxysilane with halogen group, -OC (= O) -OC ( = O) CF 3 group other than the group R 3, -OS (= O) 2 -R 3 group, -N (S (= O) 2 -R 3) 2 group , -C(S(=O) 2 -R 3 ) 3 group (R 3 is a monovalent perfluoroalkyl group having 1 to 6 carbon atoms), etc.

又,若上述通式[2]中4-c-d所表示之-X基之數為1,則可均質地形成上述保護膜,故而更佳。Furthermore, if the number of -X groups represented by 4-c-d in the general formula [2] is 1, the protective film can be uniformly formed, which is more preferable.

又,若上述通式[2]中d為0,則即便於進行後述保護膜形成後之洗淨(沖洗)之情形時,亦容易維持撥水性,故而較佳。In addition, if d in the above general formula [2] is 0, it is easier to maintain water repellency even when washing (rinsing) after formation of the protective film described later is performed, which is preferable.

進而,若上述R2 係2個-CH3 基與1個直鏈狀烷基之組合,則可均質地形成上述保護膜,故而更佳。進而,尤佳為上述R2 為3個-CH3 基。Furthermore, if the above-mentioned R 2 is a combination of two -CH 3 groups and one linear alkyl group, the above-mentioned protective film can be uniformly formed, which is more preferable. Furthermore, it is particularly preferable that the above-mentioned R 2 is three -CH 3 groups.

又,上述通式[2]所表示之矽化合物亦可為藉由反應所獲得者。In addition, the silicon compound represented by the above general formula [2] may be obtained by reaction.

又,關於相對於(I)~(III)之總量之(II)矽化合物之含量,就提高撥水性賦予效果之觀點而言較佳為0.05質量%以上,又,就成本之觀點而言較佳為20質量%以下。進而較佳為0.1~15質量%,更佳為0.2~10質量%。In addition, the content of (II) silicon compound relative to the total amount of (I) to (III) is preferably 0.05% by mass or more from the viewpoint of improving the effect of imparting water repellency, and from the viewpoint of cost Preferably it is 20 mass% or less. More preferably, it is 0.1-15 mass %, More preferably, it is 0.2-10 mass %.

[(III)非質子性溶劑] 本發明之撥水性保護膜形成用藥液含有非質子性溶劑。藉由含有非質子性溶劑,可容易地進行利用旋轉塗佈法、浸漬法或蒸氣法等進行之被處理體之表面處理。又,容易確保藥液之保管穩定性。[(III) Aprotic solvent] The chemical solution for forming a water-repellent protective film of the present invention contains an aprotic solvent. By containing an aprotic solvent, it is possible to easily perform surface treatment of the object to be treated by spin coating, dipping, or steam. In addition, it is easy to ensure the storage stability of the liquid medicine.

作為上述非質子性溶劑,例如適宜使用烴類、酯類、醚類、酮類、含鹵素溶劑、亞碸系溶劑、碸系溶劑、內酯系溶劑、碳酸酯系溶劑、多元醇之衍生物中不具有OH基者、不具有N-H基之含氮元素之溶劑、聚矽氧溶劑、萜烯系溶劑等有機溶劑、或其等之混合液。其中,若使用烴類、酯類、醚類、含鹵素溶劑、多元醇之衍生物中不具有OH基者、或其等之混合液,則可短時間地於被處理體之表面形成上述保護膜,故而更佳。As the aforementioned aprotic solvents, for example, hydrocarbons, esters, ethers, ketones, halogen-containing solvents, sulfite-based solvents, sulfite-based solvents, lactone-based solvents, carbonate-based solvents, and derivatives of polyols are suitably used. Those that do not have OH groups, nitrogen-containing solvents that do not have NH groups, organic solvents such as silicone solvents, terpene-based solvents, or their mixtures. Among them, if hydrocarbons, esters, ethers, halogen-containing solvents, polyol derivatives that do not have OH groups, or their mixtures are used, the above-mentioned protection can be formed on the surface of the object to be treated in a short time The film is therefore better.

作為上述烴類之例,有正己烷、正庚烷、正辛烷、正壬烷、正癸烷、正十一烷、正十二烷、正十四烷、正十六烷、正十八烷、正二十烷、以及其等之碳數所對應之支鏈狀之烴(例如,異十二烷、異環丁烷等)、環己烷、甲基環己烷、十氫萘、苯、甲苯、二甲苯、(鄰-、間-、或對-)二乙基苯、1,3,5-三甲基苯等,作為上述酯類之例,有乙酸乙酯、乙酸正丙酯、乙酸異丙酯、乙酸正丁酯、乙酸異丁酯、乙酸正戊酯、乙酸異戊酯、乙酸正己酯、乙酸正庚酯、乙酸正辛酯、甲酸正戊酯、丙酸正丁酯、丁酸乙酯、丁酸正丙酯、丁酸異丙酯、丁酸正丁酯、正辛酸甲酯、癸酸甲酯、丙酮酸甲酯、丙酮酸乙酯、丙酮酸正丙酯、乙醯乙酸甲酯、乙醯乙酸乙酯、2-側氧丁酸乙酯、己二酸二甲酯、3-甲氧基丙酸甲酯、3-甲氧基丙酸乙酯、3-乙氧基丙酸甲酯、3-乙氧基丙酸乙酯、乙氧基乙酸乙酯等,作為上述醚類之例,有二-正丙醚、乙基-正丁醚、二-正丁醚、乙基-正戊醚、二-正戊醚、乙基-正己醚、二-正己醚、二-正辛醚、以及其等之碳數所對應之二異丙醚、二異戊醚等具有支鏈狀烴基之醚、二甲醚、二乙醚、甲基乙基醚、甲基環戊醚、二苯醚、四氫呋喃、二㗁烷等,作為上述酮類之例,有丙酮、乙醯丙酮、甲基乙基酮、甲基丙基酮、甲基丁基酮、環己酮、異佛爾酮等,作為上述含鹵素溶劑之例,全氟辛烷、全氟壬烷、全氟環戊烷、全氟環己烷、六氟苯等全氟碳、1,1,1,3,3-五氟丁烷、八氟環戊烷、2,3-二氫十氟戊烷、ZEORORA H(日本Zeon Corporation製造)等氫氟碳、甲基全氟異丁醚、甲基全氟丁醚、乙基全氟丁醚、乙基全氟異丁醚、Asahiklin AE-3000(旭硝子製造)、Novec7100、Novec7200、Novec7300、Novec7600(均為3M製造)等氫氟醚、四氯甲烷等氯碳、氯仿等氫氯碳、二氯二氟甲烷等氯氟碳、1,1-二氯-2,2,3,3,3-五氟丙烷、1,3-二氯-1,1,2,2,3-五氟丙烷、1-氯-3,3,3-三氟丙烯、1,2-二氯-3,3,3-三氟丙烯等氫氯氟碳、全氟醚、全氟聚醚等,作為上述亞碸系溶劑之例,有二甲基亞碸等,作為上述碸系溶劑之例,有二甲基碸、二乙基碸、雙(2-羥乙基)碸、四亞甲基碸等,作為上述內酯系溶劑之例,有β-丙內酯、γ-丁內酯、γ-戊內酯、γ-己內酯、γ-庚內酯、γ-辛內酯、γ-壬內酯、γ-癸內酯、γ-十一內酯、γ-十二內酯、δ-戊內酯、δ-己內酯、δ-辛內酯、δ-壬內酯、δ-癸內酯、δ-十一內酯、δ-十二內酯、ε-己內酯等,作為上述碳酸酯系溶劑之例,有碳酸二甲酯、碳酸甲乙酯、碳酸二乙酯、碳酸丙二酯等,作為上述多元醇之衍生物中不具有OH基者之例,有乙二醇二甲醚、乙二醇二乙醚、乙二醇二丁醚、乙二醇單甲醚乙酸酯、乙二醇單乙醚乙酸酯、乙二醇單丁醚乙酸酯、乙二醇二乙酸酯、二乙二醇二甲醚、二乙二醇乙基甲基醚、二乙二醇二乙醚、二乙二醇丁基甲基醚醚、二乙二醇二丁醚、二乙二醇單甲醚乙酸酯、二乙二醇單乙醚乙酸酯、二乙二醇單丁醚乙酸酯、二乙二醇二乙酸酯、三乙二醇二甲醚、三乙二醇二乙醚、三乙二醇二丁醚、三乙二醇丁基甲基醚醚、三乙二醇單甲醚乙酸酯、三乙二醇單乙醚乙酸酯、三乙二醇單丁醚乙酸酯、三乙二醇二乙酸酯、四乙二醇二甲醚、四乙二醇二乙醚、四乙二醇二丁醚、四乙二醇單甲醚乙酸酯、四乙二醇單乙醚乙酸酯、四乙二醇單丁醚乙酸酯、四乙二醇二乙酸酯、丙二醇二甲醚、丙二醇二乙醚、丙二醇二丁醚、丙二醇單甲醚乙酸酯、丙二醇單乙醚乙酸酯、丙二醇單丁醚乙酸酯、丙二醇二乙酸酯、二丙二醇二甲醚、二丙二醇甲基丙基醚、二丙二醇二乙醚、二丙二醇二丁醚、二丙二醇單甲醚乙酸酯、二丙二醇單乙醚乙酸酯、二丙二醇單丁醚乙酸酯、二丙二醇二乙酸酯、三丙二醇二甲醚、三丙二醇二乙醚、三丙二醇二丁醚、三丙二醇單甲醚乙酸酯、三丙二醇單乙醚乙酸酯、三丙二醇單丁醚乙酸酯、三丙二醇二乙酸酯、四丙二醇二甲醚、四丙二醇單甲醚乙酸酯、四丙二醇二乙酸酯、丁二醇二甲醚、丁二醇單甲醚乙酸酯、丁二醇二乙酸酯、甘油三乙酸酯、乙酸3-甲氧基丁酯、乙酸3-甲基-3-甲氧基丁酯、丙酸3-甲基-3-甲氧基丁酯等,作為上述不具有N-H基之含氮元素之溶劑之例,有N,N-二甲基甲醯胺、N,N-二甲基乙醯胺、N-甲基-2-吡咯啶酮、N-乙基-2-吡咯啶酮、N-丙基-2-吡咯啶酮、1,3-二甲基-2-咪唑啶酮、1,3-二乙基-2-咪唑啶酮、1,3-二異丙基-2-咪唑啶酮、三乙胺、吡啶等,作為聚矽氧溶劑之例,有六甲基二矽氧烷、八甲基三矽氧烷、十甲基四矽氧烷、十二甲基五矽氧烷等,作為萜烯系溶劑之例,有對薄荷烷、二苯基薄荷烷、檸檬烯、萜品烯、莰烷、降莰烷、蒎烷等。As examples of the above hydrocarbons, there are n-hexane, n-heptane, n-octane, n-nonane, n-decane, n-undecane, n-dodecane, n-tetradecane, n-hexadecane, n-octadecane Alkane, n-eicosane, and branched hydrocarbons corresponding to their carbon numbers (for example, isododecane, isocyclobutane, etc.), cyclohexane, methylcyclohexane, decalin, Benzene, toluene, xylene, (ortho-, m-, or p-)diethylbenzene, 1,3,5-trimethylbenzene, etc., as examples of the above esters, ethyl acetate, n-propyl acetate Ester, isopropyl acetate, n-butyl acetate, isobutyl acetate, n-pentyl acetate, isoamyl acetate, n-hexyl acetate, n-heptyl acetate, n-octyl acetate, n-pentyl formate, n-butyl propionate Ester, ethyl butyrate, n-propyl butyrate, isopropyl butyrate, n-butyl butyrate, methyl n-octanoate, methyl caprate, methyl pyruvate, ethyl pyruvate, n-propyl pyruvate , Methyl Acetate, Ethyl Acetate, Ethyl 2-oxobutyrate, Dimethyl Adipate, Methyl 3-Methoxy Propionate, Ethyl 3-Methoxy Propionate, 3 -Methyl ethoxypropionate, ethyl 3-ethoxypropionate, ethyl ethoxy acetate, etc., as examples of the above ethers, there are di-n-propyl ether, ethyl-n-butyl ether, and di- N-butyl ether, ethyl-n-pentyl ether, di-n-pentyl ether, ethyl-n-hexyl ether, di-n-hexyl ether, di-n-octyl ether, and diisopropyl ether and diisopropyl ether corresponding to their carbon numbers Ethers having branched hydrocarbon groups such as amyl ether, dimethyl ether, diethyl ether, methyl ethyl ether, methyl cyclopentyl ether, diphenyl ether, tetrahydrofuran, dioxane, etc. As examples of the above ketones, acetone , Acetone, methyl ethyl ketone, methyl propyl ketone, methyl butyl ketone, cyclohexanone, isophorone, etc., as examples of the above halogen-containing solvents, perfluorooctane, perfluorononane , Perfluorocyclopentane, perfluorocyclohexane, hexafluorobenzene and other perfluorocarbons, 1,1,1,3,3-pentafluorobutane, octafluorocyclopentane, 2,3-dihydrodecafluoro Hydrofluorocarbons such as pentane, ZEORORA H (manufactured by Zeon Corporation in Japan), methyl perfluoroisobutyl ether, methyl perfluorobutyl ether, ethyl perfluorobutyl ether, ethyl perfluoroisobutyl ether, Asahiklin AE-3000 (Manufactured by Asahi Glass), Novec7100, Novec7200, Novec7300, Novec7600 (all manufactured by 3M), hydrofluoroethers, chlorocarbons such as tetrachloromethane, hydrochlorocarbons such as chloroform, chlorofluorocarbons such as dichlorodifluoromethane, 1,1- Dichloro-2,2,3,3,3-pentafluoropropane, 1,3-dichloro-1,1,2,2,3-pentafluoropropane, 1-chloro-3,3,3-trifluoro Hydrochlorofluorocarbons such as propylene, 1,2-dichloro-3,3,3-trifluoropropene, perfluoroethers, perfluoropolyethers, etc., as examples of the above-mentioned sulfite-based solvents, dimethyl sulfite, etc. As examples of the above-mentioned stubborn solvents, there are dimethyl stubborn, diethyl stubborn, bis(2-hydroxyethyl) stubborn, tetramethylene stubborn, etc., as examples of the aforementioned lactone-based solvents, there are β-propane Lactone, γ-butyrolactone, γ-valerolactone, γ-caprolactone, γ-heptanolide, γ-caprolactone, γ-nonanolactone, γ-decanolactone, γ-undecanolide Ester, γ-laurolactone, δ-pentane Lactone, δ-caprolactone, δ-caprolactone, δ-nonanolactone, δ-decanolactone, δ-undecanolide, δ-laurolactone, ε-caprolactone, etc., as the above Examples of carbonate-based solvents include dimethyl carbonate, ethyl methyl carbonate, diethyl carbonate, propylene carbonate, etc. As examples of the derivatives of the above polyols that do not have OH groups, there are ethylene glycol two Methyl ether, ethylene glycol diethyl ether, ethylene glycol dibutyl ether, ethylene glycol monomethyl ether acetate, ethylene glycol monoethyl ether acetate, ethylene glycol monobutyl ether acetate, ethylene glycol diethyl Ester, diethylene glycol dimethyl ether, diethylene glycol ethyl methyl ether, diethylene glycol diethyl ether, diethylene glycol butyl methyl ether ether, diethylene glycol dibutyl ether, diethylene glycol mono Methyl ether acetate, diethylene glycol monoethyl ether acetate, diethylene glycol monobutyl ether acetate, diethylene glycol diacetate, triethylene glycol dimethyl ether, triethylene glycol diethyl ether , Triethylene glycol dibutyl ether, triethylene glycol butyl methyl ether ether, triethylene glycol monomethyl ether acetate, triethylene glycol monoethyl ether acetate, triethylene glycol monobutyl ether acetate, Triethylene glycol diacetate, tetraethylene glycol dimethyl ether, tetraethylene glycol diethyl ether, tetraethylene glycol dibutyl ether, tetraethylene glycol monomethyl ether acetate, tetraethylene glycol monoethyl ether ethyl Ester, tetraethylene glycol monobutyl ether acetate, tetraethylene glycol diacetate, propylene glycol dimethyl ether, propylene glycol diethyl ether, propylene glycol dibutyl ether, propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether acetic acid Ester, propylene glycol monobutyl ether acetate, propylene glycol diacetate, dipropylene glycol dimethyl ether, dipropylene glycol methyl propyl ether, dipropylene glycol diethyl ether, dipropylene glycol dibutyl ether, dipropylene glycol monomethyl ether acetate, Dipropylene glycol monoethyl ether acetate, dipropylene glycol monobutyl ether acetate, dipropylene glycol diacetate, tripropylene glycol dimethyl ether, tripropylene glycol diethyl ether, tripropylene glycol dibutyl ether, tripropylene glycol monomethyl ether acetate, Tripropylene glycol monoethyl ether acetate, tripropylene glycol monobutyl ether acetate, tripropylene glycol diacetate, tetrapropylene glycol dimethyl ether, tetrapropylene glycol monomethyl ether acetate, tetrapropylene glycol diacetate, butylene glycol two Methyl ether, butylene glycol monomethyl ether acetate, butylene glycol diacetate, glycerol triacetate, 3-methoxybutyl acetate, 3-methyl-3-methoxybutyl acetate, 3-Methyl-3-methoxybutyl propionate, etc. As examples of the above-mentioned solvents containing nitrogen elements without NH groups, there are N,N-dimethylformamide and N,N-dimethyl Acetamide, N-methyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, N-propyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidone , 1,3-Diethyl-2-imidazolidinone, 1,3-diisopropyl-2-imidazolidinone, triethylamine, pyridine, etc. As examples of silicone solvents, there are hexamethyl two Silicone, octamethyltrisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane, etc. Examples of terpene-based solvents include p-menthane, diphenyl menthane, and limonene , Terpinene, campane, norbornane, pinane, etc.

又,若使用引火點超過70℃之溶劑作為上述非質子性溶劑,則就消防法上之安全性之觀點而言較佳。例如,碳酸酯系溶劑、或多元醇之衍生物中不具有OH基者多數為引火點較高者,故而可降低藥液之危險性,因此較佳。就上述安全性之觀點而言,具體而言,更佳為使用引火點超過70℃之碳酸丙二酯、乙二醇二丁醚、乙二醇單丁醚乙酸酯、乙二醇二乙酸酯、二乙二醇乙基甲基醚、二乙二醇二乙醚、二乙二醇丁基甲基醚醚、二乙二醇二丁醚、二乙二醇單甲醚乙酸酯、二乙二醇單乙醚乙酸酯、二乙二醇單丁醚乙酸酯、二乙二醇二乙酸酯、三乙二醇二甲醚、三乙二醇二乙醚、三乙二醇二丁醚、三乙二醇丁基甲基醚醚、三乙二醇單甲醚乙酸酯、三乙二醇單乙醚乙酸酯、三乙二醇單丁醚乙酸酯、三乙二醇二乙酸酯、四乙二醇二甲醚、四乙二醇二乙醚、四乙二醇二丁醚、四乙二醇單甲醚乙酸酯、四乙二醇單乙醚乙酸酯、四乙二醇單丁醚乙酸酯、四乙二醇二乙酸酯、丙二醇二乙酸酯、二丙二醇甲基丙基醚、二丙二醇單甲醚乙酸酯、二丙二醇單乙醚乙酸酯、二丙二醇單丁醚乙酸酯、二丙二醇二乙酸酯、三丙二醇二甲醚、三丙二醇二乙醚、三丙二醇二丁醚、三丙二醇單甲醚乙酸酯、三丙二醇單乙醚乙酸酯、三丙二醇單丁醚乙酸酯、三丙二醇二乙酸酯、四丙二醇二甲醚、四丙二醇單甲醚乙酸酯、四丙二醇二乙酸酯、丁二醇二乙酸酯、甘油三乙酸酯等作為上述溶劑。In addition, if a solvent with a flash point of more than 70°C is used as the aprotic solvent, it is preferable from the viewpoint of safety in the fire protection law. For example, carbonate-based solvents or polyhydric alcohol derivatives that do not have OH groups are mostly those with a higher flash point, so that the danger of the chemical liquid can be reduced, so it is preferred. From the viewpoint of the above-mentioned safety, specifically, it is more preferable to use propylene carbonate, ethylene glycol dibutyl ether, ethylene glycol monobutyl ether acetate, and ethylene glycol diethyl having a flash point of more than 70°C. Ester, diethylene glycol ethyl methyl ether, diethylene glycol diethyl ether, diethylene glycol butyl methyl ether ether, diethylene glycol dibutyl ether, diethylene glycol monomethyl ether acetate, diethyl Glycol monoethyl ether acetate, diethylene glycol monobutyl ether acetate, diethylene glycol diacetate, triethylene glycol dimethyl ether, triethylene glycol diethyl ether, triethylene glycol dibutyl ether , Triethylene glycol butyl methyl ether ether, Triethylene glycol monomethyl ether acetate, Triethylene glycol monoethyl ether acetate, Triethylene glycol monobutyl ether acetate, Triethylene glycol diacetate , Tetraethylene glycol dimethyl ether, tetraethylene glycol diethyl ether, tetraethylene glycol dibutyl ether, tetraethylene glycol monomethyl ether acetate, tetraethylene glycol monoethyl ether acetate, tetraethylene glycol mono Butyl ether acetate, tetraethylene glycol diacetate, propylene glycol diacetate, dipropylene glycol methyl propyl ether, dipropylene glycol monomethyl ether acetate, dipropylene glycol monoethyl ether acetate, dipropylene glycol monobutyl Ether acetate, dipropylene glycol diacetate, tripropylene glycol dimethyl ether, tripropylene glycol diethyl ether, tripropylene glycol dibutyl ether, tripropylene glycol monomethyl ether acetate, tripropylene glycol monoethyl ether acetate, tripropylene glycol monobutyl Ether acetate, tripropylene glycol diacetate, tetrapropylene glycol dimethyl ether, tetrapropylene glycol monomethyl ether acetate, tetrapropylene glycol diacetate, butylene glycol diacetate, glycerol triacetate, etc. are used as the above Solvent.

本發明之撥水性保護膜形成用藥液亦可進而包含聚合抑制劑、鏈轉移劑、抗氧化劑等添加劑以進而提高該藥液之穩定性。The liquid medicine for forming a water-repellent protective film of the present invention may further contain additives such as polymerization inhibitors, chain transfer agents, and antioxidants to further improve the stability of the liquid medicine.

又,上述藥液中之液相下之利用光散射式液中粒子檢測器之粒子測定中之大於0.2 μm之粒子之數量較佳為該藥液每1 mL中為100個以下。若上述大於0.2 μm之粒子之數量於該藥液每1 mL中超過100個,則有因粒子而誘發作為被處理體之晶圓之圖案損壞之虞,成為引起元件之良率降低及可靠性降低之原因,故而欠佳。又,若大於0.2 μm之粒子之數量於該藥液每1 mL中為100個以下,則可省略或減少形成上述保護膜後之利用溶劑或水之該晶圓表面(保護膜表面)之洗淨(沖洗),故而較佳。再者,上述大於0.2 μm之粒子之數量越少越好,若處於上述含量範圍內,則於該藥液每1 mL中亦可為1個以上。 再者,本發明中之藥液中之液相下之粒子測定係利用將雷射作為光源之光散射式液中粒子測定方式中之市售之測定裝置進行測定,所謂粒子之粒徑意指PSL(聚苯乙烯製乳膠)標準粒子基準之光散射當量徑。 此處,上述所謂粒子係指原料中以雜質之形式包含之塵土、灰塵、有機固形物、無機固形物等粒子、或於藥液之製備中以污染物之形式混入之塵土、灰塵、有機固形物、無機固形物等粒子,相當於最終不溶解而以粒子之形式存在於藥液中者。In addition, the number of particles larger than 0.2 μm in the particle measurement using a light scattering type particle detector in the liquid phase in the liquid drug solution is preferably 100 or less per 1 mL of the drug solution. If the number of particles larger than 0.2 μm above exceeds 100 per 1 mL of the chemical solution, the particles may induce damage to the pattern of the wafer to be processed, which may cause a decrease in the yield and reliability of the device The reason for the reduction is therefore not good. In addition, if the number of particles larger than 0.2 μm is less than 100 per 1 mL of the chemical solution, the washing of the wafer surface (protective film surface) with solvent or water after forming the protective film can be omitted or reduced. Clean (rinse), so it is better. Furthermore, the number of particles larger than 0.2 μm should be as small as possible. If it is within the above content range, there can be more than one per 1 mL of the drug solution. Furthermore, the measurement of particles in the liquid phase in the drug solution in the present invention is performed by a commercially available measurement device in the light scattering type particle measurement method in the liquid using a laser as a light source. The so-called particle size means PSL (polystyrene latex) standard particle standard light scattering equivalent diameter. Here, the above-mentioned particles refer to dust, dust, organic solids, inorganic solids and other particles contained in the form of impurities in the raw materials, or dust, dust, organic solids mixed in the form of pollutants in the preparation of the chemical solution Particles, inorganic solids and other particles are equivalent to those that do not dissolve but exist in the liquid medicine in the form of particles.

又,上述藥液中之Na、Mg、K、Ca、Mn、Fe、Cu、Li、Al、Cr、Ni、Zn及Ag之各元素(金屬雜質)之含量相對於該藥液總量較佳為分別為0.1質量ppb以下。若上述金屬雜質含量相對於該藥液總量超過0.1質量ppb,則有使元件之接合漏電流增大之虞,成為引起元件之良率降低及可靠性降低之原因,故而欠佳。又,若上述金屬雜質含量相對於該藥液總量分別為0.1質量ppb以下,則可省略或減少於作為被處理體之晶圓表面形成上述保護膜後之利用溶劑或水之該晶圓表面(保護膜表面)之洗淨(沖洗),故而較佳。因此,上述金屬雜質含量越少越好,但若處於上述含量範圍內,則各元素相對於該藥液之總量亦可為0.001質量ppb以上。In addition, the content of each element (metal impurity) of Na, Mg, K, Ca, Mn, Fe, Cu, Li, Al, Cr, Ni, Zn and Ag in the above-mentioned chemical solution is better than the total amount of the chemical solution Each is 0.1 mass ppb or less. If the metal impurity content exceeds 0.1 mass ppb with respect to the total amount of the chemical solution, the bonding leakage current of the device may increase, which may cause a decrease in the yield and reliability of the device, which is not good. In addition, if the metal impurity content relative to the total amount of the chemical solution is 0.1 mass ppb or less, the wafer surface using solvent or water after the protective film is formed on the surface of the wafer to be processed can be omitted or reduced (Protective film surface) cleaning (rinsing), so it is better. Therefore, the smaller the content of the above-mentioned metal impurities, the better, but if it is within the above-mentioned content range, the total amount of each element relative to the chemical solution may be 0.001 mass ppb or more.

2.晶圓之表面處理方法 本發明之表面處理方法之特徵在於:其具有撥水性保護膜形成步驟、及乾燥步驟,該撥水性保護膜形成步驟係於晶圓表面保持有選自由洗淨液及沖洗液所組成之群中之至少1種液體之狀態下,將該液體替換為撥水性保護膜形成用藥液且將該藥液保持於晶圓表面, 上述撥水性保護膜形成用藥液具有 (I)上述通式[1]所表示之胺基矽烷化合物、 (II)上述通式[2]所表示之矽化合物、及 (III)非質子性溶劑,且 相對於~(III)之總量之(I)之含量為0.02~0.5質量%。2. Surface treatment method of wafer The surface treatment method of the present invention is characterized in that it has a water-repellent protective film forming step, and a drying step. The water-repellent protective film forming step is maintained on the surface of the wafer selected from the group consisting of a cleaning solution and a rinsing solution In the state of at least one liquid, replace the liquid with a chemical liquid for forming a water-repellent protective film and hold the chemical liquid on the wafer surface, The above-mentioned water-repellent protective film formation chemical solution has (I) The aminosilane compound represented by the general formula [1], (II) The silicon compound represented by the general formula [2], and (III) aprotic solvent, and The content of (I) relative to the total amount of (III) is 0.02 to 0.5% by mass.

(表面處理態樣1) 如圖1所示,至少將(I)、(II)、及(III)混合而製成溶液(撥水性保護膜形成用藥液),將該藥液以液體狀態或氣體狀態供給至晶圓表面而使液體狀態之撥水性保護膜形成用藥液保持於該晶圓表面。 上述藥液之供給係於洗淨液或沖洗液等液體保持於晶圓表面之狀態下進行,且將該液體替換為藥液。替換時,保持於晶圓表面之狀態之洗淨液或沖洗液等液體並無特別限定,一般為2-丙醇(iPA)等。 藉由利用上述替換將藥液保持於晶圓表面而於晶圓表面形成撥水性保護膜。亦可視需要將晶圓表面之上述藥液替換為沖洗液而進一步實施沖洗處理。 繼而,藉由乾燥自晶圓表面將液體去除。由於晶圓表面形成有撥水性保護膜,故而可藉由優異之撥水性減少乾燥時之圖案崩塌。 再者,作為藉由乾燥去除之液體,可列舉上述撥水性保護膜形成用藥液、沖洗液、或其等之混合液。再者,所去除之液體為沖洗液時,有將上述藥液替換為沖洗液而進一步實施沖洗處理之情形。又,所去除之液體為上述藥液與沖洗液之混合液時,可為將上述藥液替換為沖洗液之中途狀態之「混合液」之情形,亦可為使用預先將藥液原料溶解至沖洗液而成之「混合液」替換上述藥液之情形。於後述表面處理態樣2~6中亦同。 再者,於表面處理態樣1中,將作為藥液之原料之(I)~(III)進行混合之順序並無特別限定,較佳為將(I)或(II)混合至(III)非質子性溶劑。(Surface treatment aspect 1) As shown in Figure 1, at least (I), (II), and (III) are mixed to form a solution (a chemical solution for forming a water-repellent protective film), and the chemical solution is supplied to the wafer surface in a liquid or gas state The liquid chemical for forming a water-repellent protective film is held on the surface of the wafer. The supply of the above-mentioned chemical liquid is carried out in a state where a liquid such as a cleaning liquid or a rinse liquid is held on the surface of the wafer, and the liquid is replaced with a chemical liquid. At the time of replacement, there is no particular limitation on the liquid such as a cleaning solution or a rinsing solution maintained on the surface of the wafer, and it is generally 2-propanol (iPA). A water-repellent protective film is formed on the surface of the wafer by holding the chemical solution on the surface of the wafer by using the above replacement. If necessary, the above-mentioned chemical solution on the surface of the wafer can be replaced with a rinse solution for further rinse processing. Then, the liquid is removed from the wafer surface by drying. Since the water-repellent protective film is formed on the surface of the wafer, the excellent water-repellency can reduce pattern collapse during drying. Furthermore, as the liquid to be removed by drying, the above-mentioned water-repellent protective film forming chemical liquid, rinse liquid, or a mixed liquid thereof can be cited. Furthermore, when the liquid to be removed is a rinsing liquid, there are cases in which the above-mentioned chemical liquid is replaced with a rinsing liquid to further perform a rinsing process. In addition, when the liquid to be removed is a mixed liquid of the above-mentioned chemical liquid and the rinse liquid, it may be the case where the above-mentioned chemical liquid is replaced with a "mixed liquid" in the middle of the rinse liquid, or the raw material of the chemical liquid is dissolved in advance When the "mixed solution" made from the rinse solution replaces the above-mentioned chemical solution. The same applies to surface treatment aspects 2 to 6 described later. Furthermore, in the surface treatment aspect 1, the order of mixing (I) to (III) as the raw materials of the chemical liquid is not particularly limited, and it is preferable to mix (I) or (II) to (III) Aprotic solvent.

又,本發明之表面處理方法亦可於上述撥水性保護膜形成步驟之前進而具有藥液製備步驟,該藥液製備步驟係使質子性化合物與具有 (II)上述通式[2]所表示之矽化合物、 (IV)上述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(III)或具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液。 使質子性化合物與原料藥液接觸之方法並無特別限定,可採用公知之方法。再者,於藉由上述接觸製備撥水性保護膜形成用藥液時,雖然詳情並不明確,但認為如下述反應式所示,上述通式[2]所表示之矽化合物與質子性化合物(A-H)進行反應而生成之反應產物(X-H;酸性化合物)與上述通式[4]所表示之矽氮烷化合物進行反應,藉此生成上述通式[1]所表示之胺基矽烷化合物,其結果為,獲得具有上述(I)~(III)或具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液。 [化18]

Figure 02_image039
可採用後述表面處理態樣2~3作為該表面處理方法。In addition, the surface treatment method of the present invention may further have a chemical solution preparation step before the water-repellent protective film formation step. The chemical solution preparation step is to combine a protic compound with a compound having (II) represented by the general formula [2] Silicon compound, (IV) silazane compound represented by the general formula [4], and (III) aprotic solvent raw material drug liquid relative to the total amount of (II), (III), (IV) 1 kg is contacted at a ratio of 0.001 to 0.3 mol, thereby preparing (I) having the above (I) to (III) or having the above (I) to (IV) relative to the total amount of (I) to (III) ) The content of the water-repellent protective film is 0.02-0.5% by mass. The method of bringing the protic compound into contact with the raw drug solution is not particularly limited, and a known method can be used. Furthermore, when the chemical solution for forming a water-repellent protective film is prepared by the above contact, although the details are not clear, it is thought that the silicon compound represented by the above general formula [2] and the protic compound (AH ) The reaction product (XH; acidic compound) produced by the reaction reacts with the silazane compound represented by the general formula [4], thereby producing the aminosilane compound represented by the general formula [1], as a result To obtain water repellency with the above (I) to (III) or the above (I) to (IV) and the content of (I) relative to the total amount of (I) to (III) of 0.02 to 0.5% by mass Chemical solution for forming protective film. [化18]
Figure 02_image039
The surface treatment modes 2 to 3 described later can be used as the surface treatment method.

(表面處理態樣2) 如圖2所示,至少將(II)、(III)、及(IV)混合而製成溶液(原料藥液),使質子性化合物以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率接觸該原料藥液而製備撥水性保護膜形成用藥液。上述接觸所使用之質子性化合物可為利用非質子性溶劑進行稀釋而成者(於不相溶之情形時為分散之狀態)。作為該稀釋所使用之非質子性溶劑,可列舉作為本發明之(III)所說明者。 藥液製備步驟中所使用之原料藥液及質子性化合物可為液體狀態,亦可為氣體狀態。例如,可於腔室內之容器中、槽中或合流點以下之配管中將液體狀態之兩者混合,可於腔室內、氣化室中或氣化後之合流點以下之配管中將氣體狀態之兩者混合,亦可將腔室內之容器中之液體狀態之原料藥液曝露於氣體狀態之質子性化合物而使其等接觸。再者,該原料藥液中可包含(I)。(Surface treatment aspect 2) As shown in Figure 2, at least (II), (III), and (IV) are mixed to form a solution (raw drug solution), and the protic compound is compared with (II), (III), (IV) The total amount of 1 kg is contacted with the raw drug solution at a ratio of 0.001 to 0.3 mol to prepare a drug solution for forming a water-repellent protective film. The protic compound used in the above-mentioned contact may be diluted with an aprotic solvent (in the case of immiscibility, it is in a dispersed state). Examples of the aprotic solvent used for this dilution include those described in (III) of the present invention. The crude drug solution and protic compound used in the preparation step of the drug solution may be in a liquid state or a gas state. For example, the two liquid states can be mixed in the container, tank, or pipe below the junction point in the chamber, and the gas state can be mixed in the chamber, in the vaporization chamber, or in the pipe below the junction point after vaporization. When the two are mixed, the liquid raw material drug solution in the liquid state of the container in the chamber can be exposed to the gaseous protic compound to make contact. Furthermore, (I) may be contained in the bulk drug solution.

就提高撥水性賦予效果之觀點而言,上述質子性化合物較佳為具有-OH基、及/或-NH2 基之化合物,尤佳為具有-OH基之化合物、及/或NH3 。進而,較佳為水、及/或碳數為6個以下之醇,尤其更佳為水、及/或2-丙醇。From the viewpoint of improving the effect of imparting water repellency, the protic compound is preferably a compound having an -OH group and/or a -NH 2 group, and particularly preferably a compound having an -OH group and/or NH 3 . Furthermore, water and/or an alcohol having 6 or less carbon atoms is preferable, and water and/or 2-propanol are more preferable.

作為上述碳數為6個以下之醇之例,除甲醇、乙醇、直鏈或支鏈之丙醇、丁醇、戊醇、己醇外,亦可列舉多元醇或具有OH基之多元醇之衍生物。作為上述多元醇之例,有乙二醇、二乙二醇、二丙二醇、三乙二醇、1,2-丙二醇、1,3-丙二醇、1,2-丁二醇、1,3-丁二醇、1,4-丁二醇、甘油等,作為上述具有-OH基之多元醇之衍生物之例,可列舉:乙二醇單甲醚、乙二醇單乙醚、乙二醇單丙醚、乙二醇單丁醚、丙二醇單甲醚、丙二醇單乙醚、丙二醇單丙醚、丁二醇單甲醚、二乙二醇單甲醚、二乙二醇單乙醚等。As examples of the alcohols with 6 or less carbon atoms, in addition to methanol, ethanol, linear or branched propanol, butanol, pentanol, and hexanol, polyhydric alcohols or polyhydric alcohols with OH groups can also be cited derivative. As examples of the above-mentioned polyols, there are ethylene glycol, diethylene glycol, dipropylene glycol, triethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-butane Glycol, 1,4-butanediol, glycerin, etc., as examples of the derivatives of the above-OH group-containing polyhydric alcohols, include: ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropylene Ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, butylene glycol monomethyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, etc.

又,若使質子性化合物以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,則於上述撥水性保護膜形成用藥液中,容易將相對於(I)~(III)之總量之(I)之含量可知為0.02~0.5質量%,故而較佳。上述使質子性化合物進行接觸之比率更佳為0.003~0.2莫耳之比率,尤佳為0.003~0.1莫耳之比率。In addition, if the protic compound is brought into contact at a ratio of 0.001 to 0.3 mol with respect to 1 kg of the total amount of (II), (III), and (IV), it will be easier to use in the above-mentioned water-repellent protective film formation chemical solution The content of (I) relative to the total amount of (I) to (III) is found to be 0.02 to 0.5% by mass, which is preferable. The ratio at which the protic compound is brought into contact is more preferably a ratio of 0.003 to 0.2 mol, and particularly preferably a ratio of 0.003 to 0.1 mol.

繼而,向晶圓表面以液體狀態或氣體狀態供給所獲得之藥液而使液體狀態之撥水性保護膜形成用藥液保持於該晶圓表面。再者,向晶圓表面供給相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之範圍之狀態的藥液以如上所述般藉由反應生成(I)胺基矽烷。另一方面,由於可輕易忽略副反應等對藥液組成之影響,故而較佳為向晶圓表面供給自上述接觸起1日以內之藥液,更佳為向晶圓表面供給自上述接觸起5小時以內之藥液,尤佳為向晶圓表面供給自上述接觸起1小時以內之藥液。 上述藥液之供給係於洗淨液或沖洗液等液體保持於晶圓表面之狀態下進行,且利用藥液替換該液體。再者,於上述洗淨液或沖洗液等液體為質子性化合物之情形時,有如下可能性,即,於上述替換過程中進而接觸質子性化合物,上述(II)與質子性化合物進行反應,反應產物(酸性化合物)進而與上述(IV)進行反應,藉此新生成上述(I)。然而,於上述替換中,上述洗淨液或沖洗液等液體被迅速替換成撥水性保護膜形成用藥液,因此幾乎不存在上述(II)與質子性化合物進行反應之影響。因此,於上述替換時,如上所述之新生成(I)之影響為可忽略之程度。替換時保持於晶圓表面之狀態之洗淨液或沖洗液等液體並無特別限定,一般為2-丙醇(iPA)等。 藉由利用上述替換將藥液保持於晶圓表面而於晶圓表面形成撥水性保護膜。亦可視需要將晶圓表面之上述藥液替換為沖洗液而進而實施沖洗處理。 繼而,藉由乾燥自晶圓表面將液體去除。由於晶圓表面形成有撥水性保護膜,故而可藉由優異之撥水性減少乾燥時之圖案崩塌。再者,作為藉由乾燥而去除之液體,可列舉上述撥水性保護膜形成用藥液、沖洗液、或其等之混合液。Then, the obtained chemical solution is supplied to the surface of the wafer in a liquid state or a gas state, and the chemical solution for forming a water-repellent protective film in a liquid state is held on the wafer surface. Furthermore, the chemical solution in a state in which the content of (I) relative to the total amount of (I) to (III) is in the range of 0.02 to 0.5% by mass is supplied to the wafer surface to generate (I) by the reaction as described above. ) Aminosilane. On the other hand, since the influence of side reactions on the composition of the chemical solution can be easily ignored, it is preferable to supply the chemical solution to the wafer surface within 1 day from the above contact, and it is more preferable to supply the chemical solution to the wafer surface since the contact The chemical solution within 5 hours is particularly preferred to supply the chemical solution to the wafer surface within 1 hour from the above contact. The supply of the above-mentioned chemical liquid is carried out in a state where a liquid such as a cleaning liquid or a rinse liquid is maintained on the surface of the wafer, and the liquid is replaced with the chemical liquid. Furthermore, when the liquid such as the washing liquid or the rinse liquid is a protic compound, there is a possibility that the protic compound is further contacted during the replacement process, and the above (II) reacts with the protic compound, The reaction product (acidic compound) further reacts with the above (IV), thereby newly forming the above (I). However, in the above replacement, the liquid such as the cleaning liquid or the rinse liquid is quickly replaced with the water-repellent protective film forming chemical liquid, so there is almost no influence of the reaction of the above-mentioned (II) with the protic compound. Therefore, in the above replacement, the influence of the new generation (I) described above is negligible. There is no particular limitation on the liquid such as cleaning liquid or rinsing liquid that remains on the surface of the wafer during replacement, and is generally 2-propanol (iPA). A water-repellent protective film is formed on the surface of the wafer by holding the chemical solution on the surface of the wafer by using the above replacement. Optionally, the above-mentioned chemical solution on the surface of the wafer can be replaced with a rinse solution for further rinse treatment. Then, the liquid is removed from the wafer surface by drying. Since the water-repellent protective film is formed on the surface of the wafer, the excellent water-repellency can reduce pattern collapse during drying. Furthermore, as the liquid to be removed by drying, the above-mentioned water-repellent protective film forming chemical liquid, rinse liquid, or a mixed liquid thereof can be cited.

(表面處理態樣3) 如圖3所示,至少將(II)、(III)、及(IV)混合而製成溶液(原料藥液),向晶圓表面以液體狀態或氣體狀態供給該原料藥液而使液體狀態之原料藥液保持於該晶圓表面。 上述原料藥液之供給係於洗淨液或沖洗液等液體保持於晶圓表面之狀態下進行,且利用原料藥液替換該液體。再者,於上述洗淨液或沖洗液等液體為水或醇等質子性化合物之情形時,有如下可能性,即,於上述替換過程中上述(II)與質子性化合物進行反應,反應產物(酸性化合物)進而與上述(IV)進行反應,藉此生成上述(I)。然而,於上述替換中,由於上述洗淨液或沖洗液等液體被迅速替換成原料藥液,因此幾乎不存在上述(II)與質子性化合物進行反應之影響。因此,於上述替換時,如上所述之新生成(I)之影響為可忽略之程度。替換時保持於晶圓表面之狀態之洗淨液或沖洗液等液體並無特別限定,一般為2-丙醇(iPA)等。 其次,使質子性化合物以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率接觸該原料藥液而於晶圓表面製備撥水性保護膜形成用藥液。再者,為了如上所述般藉由反應生成(I)胺基矽烷,以相對於(I)~(III)之總量之(I)之含量成為0.02~0.5質量%之範圍之方式將藥液保持於晶圓表面。 上述接觸所使用之質子性化合物可為利用非質子性溶劑進行稀釋而成者(於不相溶之情形時為分散之狀態)。作為該稀釋所使用之非質子性溶劑,可列舉作為本發明之(III)所說明者。藥液製備步驟中所使用之質子性化合物可為液體狀態,亦可為氣體狀態。例如,可於腔室內向保持於晶圓表面之液體狀態之原料藥液添加液體狀態之質子性化合物,亦可於腔室內使保持於晶圓表面之液體狀態之原料藥液曝露於氣體狀態之質子性化合物而使其等接觸。於後者之情形時,例如亦可使腔室內成為特定濃度之質子性化合物之蒸氣環境而進行原料藥液之供給。 又,於使原料藥液與氣體狀態之質子性化合物接觸之情形時,若於晶圓表面擴散溶液狀態之原料藥液而使其與氣體狀態之質子性化合物接觸,則可擴大接觸面積,可於短時間內導入質子性化合物,故而較佳。此時,空間中之氣體狀態之質子性化合物之濃度較佳為0.05~5體積%,進而較佳為0.1~2體積%。又,接觸時間較佳為0.1~600秒,進而較佳為2~180秒。於晶圓表面擴散原料藥液之方法可適當使用公知之方法,尤佳為旋轉塗佈法。 藉由將以上述方式製備之藥液保持於晶圓表面而於晶圓表面形成撥水性保護膜。亦可視需要將晶圓表面之上述藥液替換為沖洗液而進而實施沖洗處理。 繼而,藉由乾燥自晶圓表面將液體去除。由於晶圓表面形成有撥水性保護膜,故而可藉由優異之撥水性減少乾燥時之圖案崩塌。再者,作為藉由乾燥而去除之液體,可列舉上述撥水性保護膜形成用藥液、沖洗液、或其等之混合液。(Surface treatment aspect 3) As shown in FIG. 3, at least (II), (III), and (IV) are mixed to form a solution (raw drug solution), and the bulk drug solution is supplied to the wafer surface in a liquid state or a gas state to make the liquid state The raw material liquid is kept on the surface of the wafer. The supply of the above-mentioned bulk chemical solution is performed in a state in which a liquid such as a cleaning solution or a rinse liquid is maintained on the wafer surface, and the bulk chemical solution is used to replace the liquid. Furthermore, when the liquid such as the washing liquid or the rinsing liquid is a protic compound such as water or alcohol, there is a possibility that the above-mentioned (II) reacts with the protic compound in the above-mentioned replacement process, and the reaction product The (acidic compound) further reacts with the above (IV) to thereby produce the above (I). However, in the above-mentioned replacement, since the liquid such as the cleaning liquid or the rinse liquid is quickly replaced with the bulk chemical liquid, there is almost no influence of the reaction of the above-mentioned (II) with the protic compound. Therefore, in the above replacement, the influence of the new generation (I) described above is negligible. There is no particular limitation on the liquid such as cleaning liquid or rinsing liquid that remains on the surface of the wafer during replacement, and is generally 2-propanol (iPA). Next, the protic compound is brought into contact with the raw chemical solution at a ratio of 0.001 to 0.3 mol relative to 1 kg of the total amount of (II), (III), and (IV) to prepare a water-repellent protective film forming drug on the wafer surface liquid. Furthermore, in order to produce (I) aminosilane by the reaction as described above, the drug is added so that the content of (I) relative to the total amount of (I) to (III) is in the range of 0.02 to 0.5 mass% The liquid remains on the surface of the wafer. The protic compound used in the above-mentioned contact may be diluted with an aprotic solvent (in the case of immiscibility, it is in a dispersed state). Examples of the aprotic solvent used for this dilution include those described in (III) of the present invention. The protic compound used in the liquid preparation step may be in a liquid state or in a gas state. For example, it is possible to add a protic compound in the liquid state to the chemical raw material in the liquid state maintained on the wafer surface in the chamber, or to expose the chemical raw material in the liquid state maintained on the wafer surface to the gaseous state in the chamber. Protic compounds are brought into contact. In the latter case, for example, the chamber may be made into a vapor environment of a protic compound with a specific concentration to supply the crude drug solution. In addition, in the case of contacting the chemical raw material with the protic compound in the gas state, if the chemical raw material in the solution state is diffused on the surface of the wafer to contact the protic compound in the gas state, the contact area can be enlarged. It is preferable to introduce protic compounds in a short time. At this time, the concentration of the protic compound in the gas state in the space is preferably 0.05-5 vol%, and more preferably 0.1-2 vol%. In addition, the contact time is preferably 0.1 to 600 seconds, and more preferably 2 to 180 seconds. The method of spreading the raw material liquid on the surface of the wafer can appropriately use a known method, and a spin coating method is particularly preferred. The water-repellent protective film is formed on the surface of the wafer by holding the chemical solution prepared in the above manner on the surface of the wafer. Optionally, the above-mentioned chemical solution on the surface of the wafer can be replaced with a rinse solution for further rinse treatment. Then, the liquid is removed from the wafer surface by drying. Since the water-repellent protective film is formed on the surface of the wafer, the excellent water-repellency can reduce pattern collapse during drying. Furthermore, as the liquid to be removed by drying, the above-mentioned water-repellent protective film forming chemical liquid, rinse liquid, or a mixed liquid thereof can be cited.

又,本發明之表面處理方法亦可於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使上述通式[6]所表示之酸性化合物與具有 (IV)上述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(III)或具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液。 使酸性化合物與原料藥液接觸之方法並無特別限定,可採用公知之方法。再者,於藉由上述接觸製備撥水性保護膜形成用藥液時,雖然詳情並不明確,但認為人下述反應式所示,上述通式[4]所表示之矽氮烷化合物與上述通式[6]所表示之酸性化合物進行反應,藉此生成上述通式[1]所表示之胺基矽烷化合物及上述通式[2]所表示之矽化合物,其結果為,獲得具有上述(I)~(III)或具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液。 [化19]

Figure 02_image041
又,若使酸性化合物以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,則於上述撥水性保護膜形成用藥液中,容易將相對於(I)~(III)之總量之(I)之含量控制為0.02~0.5質量%,因此較佳。上述使酸性化合物進行接觸之比率更佳為0.003~0.2莫耳之比率,尤佳為0.003~0.1莫耳之比率。 可採用後述之表面處理態樣4~5作為該表面處理方法。In addition, the surface treatment method of the present invention may also have a chemical solution preparation step before the water-repellent protective film forming step. The chemical solution preparation step is to combine the acidic compound represented by the general formula [6] with the acid compound having the general formula (IV) The silazane compound represented by formula [4] and (III) aprotic solvent raw material liquid are contacted at a ratio of 0.001 to 0.3 mol relative to the total amount of (III) and (IV) 1 kg. Thereby, the water repellency having the above (I) to (III) or the above (I) to (IV) and the content of (I) relative to the total amount of (I) to (III) is prepared with a water repellency of 0.02 to 0.5% by mass Chemical solution for forming protective film. The method of bringing the acidic compound into contact with the crude drug solution is not particularly limited, and a known method can be used. Furthermore, when the chemical solution for forming a water-repellent protective film is prepared by the above contact, although the details are not clear, it is believed that the silazane compound represented by the above general formula [4] is as shown in the following reaction formula. The acidic compound represented by the formula [6] reacts to produce the aminosilane compound represented by the general formula [1] and the silicon compound represented by the general formula [2]. As a result, the compound having the above (I ) To (III) or having the above (I) to (IV) and the content of (I) relative to the total amount of (I) to (III) is 0.02 to 0.5% by mass for forming a water-repellent protective film. [化19]
Figure 02_image041
In addition, if the acidic compound is brought into contact at a ratio of 0.001 to 0.3 mol relative to 1 kg of the total amount of (III) and (IV), it will be easier to compare the chemical solution for forming a water-repellent protective film with respect to (I). The content of (I) in the total amount of) to (III) is controlled to be 0.02 to 0.5% by mass, which is preferable. The above-mentioned ratio of contacting the acidic compound is more preferably a ratio of 0.003 to 0.2 mol, and particularly preferably a ratio of 0.003 to 0.1 mol. The surface treatment modes 4 to 5 described later can be used as the surface treatment method.

(表面處理態樣4) 如圖4所示,至少將(III)及(IV)混合而製成溶液(原料藥液),使上述通式[6]所表示之酸性化合物以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率與該原料藥液接觸而製備撥水性保護膜形成用藥液。上述接觸所使用之酸性化合物可為利用非質子性溶劑進行稀釋而成者(於不相溶之情形時為分散之狀態)。作為該稀釋所使用之非質子性溶劑,可列舉作為本發明之(III)所說明者。 藥液製備步驟中所使用之原料藥液及酸性化合物可為液體狀態,亦可為氣體狀態。例如,可於腔室內之容器中、槽中或合流點以下之配管中將液體狀態之兩者混合,可於腔室內、氣化室中或氣化後之合流點以下之配管中將氣體狀態之兩者混合,亦可將腔室內之容器中之液體狀態之原料藥液曝露於氣體狀態之酸性化合物而使其等接觸。 繼而,向晶圓表面以液體狀態或氣體狀態供給所獲得之藥液而使液體狀態之撥水性保護膜形成用藥液保持於該晶圓表面。再者,為了如上所述般藉由反應生成(I)胺基矽烷,向晶圓表面供給相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之範圍之狀態之藥液。另一方面,由於可輕易忽略副反應等對藥液組成之影響,故而較佳為向晶圓表面供給自上述接觸起1日以內之藥液,更佳為向晶圓表面供給自上述接觸起5小時以內之藥液,尤佳為向晶圓表面供給自上述接觸起1小時以內之藥液。 上述藥液之供給係於洗淨液或沖洗液等液體保持於晶圓表面之狀態下進行,且利用藥液替換該液體。替換時保持於晶圓表面之狀態之洗淨液或沖洗液等液體並無特別限定,一般為2-丙醇(iPA)等。 藉由利用上述替換將藥液保持於晶圓表面而於晶圓表面形成撥水性保護膜。亦可視需要將晶圓表面之上述藥液替換為沖洗液而進而實施沖洗處理。 繼而,藉由乾燥自晶圓表面將液體去除。由於晶圓表面形成有撥水性保護膜,故而可藉由優異之撥水性減少乾燥時之圖案崩塌。再者,作為藉由乾燥而去除之液體,可列舉上述撥水性保護膜形成用藥液、沖洗液、或其等之混合液。(Surface treatment aspect 4) As shown in Figure 4, at least (III) and (IV) are mixed to form a solution (raw drug solution), and the acidic compound represented by the general formula [6] is relative to the total of (III) and (IV) The amount of 1 kg is 0.001-0.3 mol in a ratio of 0.001 to 0.3 mol to contact the raw material liquid to prepare a water-repellent protective film forming liquid. The acidic compound used in the aforementioned contact may be diluted with an aprotic solvent (in the case of immiscibility, it is in a dispersed state). Examples of the aprotic solvent used for this dilution include those described in (III) of the present invention. The crude drug solution and acidic compound used in the drug solution preparation step may be in a liquid state or in a gas state. For example, the two liquid states can be mixed in the container, tank, or pipe below the junction point in the chamber, and the gas state can be mixed in the chamber, in the vaporization chamber, or in the pipe below the junction point after vaporization. When the two are mixed, the liquid raw material in the container in the chamber can also be exposed to the acidic compound in the gaseous state to make contact. Then, the obtained chemical solution is supplied to the surface of the wafer in a liquid state or a gas state, and the chemical solution for forming a water-repellent protective film in a liquid state is held on the wafer surface. Furthermore, in order to produce (I) aminosilane by reaction as described above, the content of (I) relative to the total amount of (I) to (III) is supplied to the wafer surface in the range of 0.02 to 0.5 mass% The state of the liquid medicine. On the other hand, since the influence of side reactions on the composition of the chemical solution can be easily ignored, it is preferable to supply the chemical solution to the wafer surface within 1 day from the above contact, and it is more preferable to supply the chemical solution to the wafer surface since the contact The chemical solution within 5 hours is particularly preferred to supply the chemical solution to the wafer surface within 1 hour from the above contact. The supply of the above-mentioned chemical liquid is carried out in a state where a liquid such as a cleaning liquid or a rinse liquid is maintained on the surface of the wafer, and the liquid is replaced with the chemical liquid. There is no particular limitation on the liquid such as cleaning liquid or rinsing liquid that remains on the surface of the wafer during replacement, and is generally 2-propanol (iPA). A water-repellent protective film is formed on the surface of the wafer by holding the chemical solution on the surface of the wafer by using the above replacement. Optionally, the above-mentioned chemical solution on the surface of the wafer can be replaced with a rinse solution for further rinse treatment. Then, the liquid is removed from the wafer surface by drying. Since the water-repellent protective film is formed on the surface of the wafer, the excellent water-repellency can reduce pattern collapse during drying. Furthermore, as the liquid to be removed by drying, the above-mentioned water-repellent protective film forming chemical liquid, rinse liquid, or a mixed liquid thereof can be cited.

(表面處理態樣5) 如圖5所示,至少將(III)及(IV)混合而製成溶液(原料藥液),向晶圓表面以液體狀態或氣體狀態供給該原料藥液而使液體狀態之原料藥液保持於該晶圓表面。 上述原料藥液之供給係於洗淨液或沖洗液等液體保持於晶圓表面之狀態下進行,且利用原料藥液替換該液體。替換時保持於晶圓表面之狀態之洗淨液或沖洗液等液體並無特別限定,一般為2-丙醇(iPA)等。 其次,使酸性化合物以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率接觸該原料藥液而於晶圓表面製備撥水性保護膜形成用藥液。再者,為了如上所述般藉由反應生成(I)胺基矽烷,以相對於(I)~(III)之總量之(I)之含量成為0.02~0.5質量%之範圍之方式將藥液保持於晶圓表面。 上述接觸所使用之酸性化合物可為利用非質子性溶劑進行稀釋而成者(於不相溶之情形時為分散之狀態)。作為該稀釋所使用之非質子性溶劑,可列舉作為本發明之(III)所說明者。藥液製備步驟中所使用之酸性化合物可為液體狀態,亦可為氣體狀態。例如,可於腔室內向保持於晶圓表面之液體狀態之原料藥液添加液體狀態之酸性化合物,亦可於腔室內將保持於晶圓表面之液體狀態之原料藥液曝露於氣體狀態之酸性化合物而使其等接觸。於後者之情形時,例如亦可使腔室內成為特定濃度之酸性化合物之蒸氣環境而進行原料藥液之供給。 又,於使原料藥液與氣體狀態之酸性化合物接觸之情形時,若於晶圓表面擴散溶液狀態之原料藥液而使之與氣體狀態之酸性化合物接觸,則可擴大接觸面積,可於短時間內導入酸性化合物,故而較佳。此時,空間中之氣體狀態之酸性化合物之濃度較佳為0.05~5體積%,進而較佳為0.1~2體積%。又,接觸時間較佳為0.01~600秒,進而較佳為0.1~180秒。於晶圓表面擴散原料藥液之方法可適當使用公知之方法,尤佳為旋轉塗佈法。 藉由將以上述方式製備之藥液保持於晶圓表面而於晶圓表面形成撥水性保護膜。亦可視需要將晶圓表面之上述藥液替換為沖洗液而進而實施沖洗處理。 繼而,藉由乾燥自晶圓表面將液體去除。由於晶圓表面形成有撥水性保護膜,故而可藉由優異之撥水性減少乾燥時之圖案崩塌。再者,作為藉由乾燥而去除之液體,可列舉上述撥水性保護膜形成用藥液、沖洗液、或其等之混合液。(Surface treatment aspect 5) As shown in Figure 5, at least (III) and (IV) are mixed to form a solution (raw drug solution), and the drug substance is supplied to the surface of the wafer in a liquid or gas state to keep the drug substance in a liquid state On the surface of the wafer. The supply of the above-mentioned bulk chemical solution is performed in a state in which a liquid such as a cleaning solution or a rinse liquid is maintained on the wafer surface, and the bulk chemical solution is used to replace the liquid. There is no particular limitation on the liquid such as cleaning liquid or rinsing liquid that remains on the surface of the wafer during replacement, and is generally 2-propanol (iPA). Next, the acidic compound is brought into contact with the raw chemical solution at a ratio of 0.001 to 0.3 mol relative to the total amount of (III) and (IV) 1 kg to prepare a water-repellent protective film forming chemical solution on the wafer surface. Furthermore, in order to produce (I) aminosilane by the reaction as described above, the drug is added so that the content of (I) relative to the total amount of (I) to (III) is in the range of 0.02 to 0.5 mass% The liquid remains on the surface of the wafer. The acidic compound used in the aforementioned contact may be diluted with an aprotic solvent (in the case of immiscibility, it is in a dispersed state). Examples of the aprotic solvent used for this dilution include those described in (III) of the present invention. The acidic compound used in the preparation step of the liquid medicine may be in a liquid state or in a gas state. For example, it is possible to add an acidic compound in the liquid state to the chemical raw material in the liquid state maintained on the wafer surface in the chamber, or to expose the chemical raw material in the liquid state maintained on the wafer surface to the acidic acid in the gas state in the chamber Compound and bring it into contact. In the latter case, for example, the chamber may be made into a vapor environment with a specific concentration of acidic compound to supply the raw chemical liquid. In addition, when the raw chemical liquid is brought into contact with the acidic compound in the gaseous state, if the raw chemical liquid in the solution state is diffused on the surface of the wafer to make it contact with the acidic compound in the gas state, the contact area can be enlarged, and the contact area can be shortened. It is better to introduce acidic compounds within time. At this time, the concentration of the acidic compound in the gas state in the space is preferably 0.05 to 5% by volume, and more preferably 0.1 to 2% by volume. In addition, the contact time is preferably 0.01 to 600 seconds, and more preferably 0.1 to 180 seconds. The method of spreading the raw material liquid on the surface of the wafer may appropriately use a known method, and a spin coating method is particularly preferred. The water-repellent protective film is formed on the surface of the wafer by holding the chemical solution prepared in the above manner on the surface of the wafer. Optionally, the above-mentioned chemical solution on the surface of the wafer can be replaced with a rinse solution for further rinse treatment. Then, the liquid is removed from the wafer surface by drying. Since the water-repellent protective film is formed on the surface of the wafer, the excellent water-repellency can reduce pattern collapse during drying. Furthermore, as the liquid to be removed by drying, the above-mentioned water-repellent protective film forming chemical liquid, rinse liquid, or a mixed liquid thereof can be cited.

又,亦可採用後述之表面處理態樣6作為表面處理方法。In addition, the surface treatment aspect 6 described later can also be used as the surface treatment method.

(表面處理態樣6) 若實施例如利用具有氨成分之SC-1進行之前處理,則有包含來自氨成分之NH2 基之成分(質子性化合物)於晶圓表面為分子等級且容易殘留之傾向。如圖6所示,對上述包含NH2 基之成分(質子性化合物)為分子等級且以特定量殘留之晶圓表面,以液體狀態或氣體狀態供給至少將(II)、(III)、及(IV)混合而獲得之溶液(原料藥液),從而將上述SC-1或於SC-1處理後替換之洗淨液等替換為液體狀態之原料藥液。繼而,具有撥水性保護膜形成步驟、及乾燥步驟,該撥水性保護膜形成步驟係使該原料藥液與上述分子等級且以特定量殘留之包含NH2 基之成分(質子性化合物)接觸,而於晶圓表面製備本發明所記載之撥水性保護膜形成用藥液,並將該藥液保持於晶圓表面。(Surface treatment aspect 6) If, for example, the SC-1 with ammonia component is used for the pretreatment, the component (protic compound) containing the NH 2 group derived from the ammonia component is molecular level and easy to remain on the wafer surface tendency. As shown in FIG. 6, the above-mentioned NH 2 group-containing component (protic compound) is at the molecular level and remains in a specific amount on the wafer surface, and at least (II), (III), and (IV) The solution (raw drug solution) obtained by mixing, so as to replace the above-mentioned SC-1 or the cleaning solution replaced after SC-1 treatment with a liquid bulk drug solution. Then, there is a water-repellent protective film forming step and a drying step. The water-repellent protective film forming step involves contacting the crude drug solution with a component (protic compound) containing an NH 2 group remaining in a specific amount at the molecular level. The water-repellent protective film forming chemical solution described in the present invention is prepared on the wafer surface, and the chemical solution is maintained on the wafer surface.

就容易抑制反應之放熱之觀點而言,較佳為表面處理態樣3。From the viewpoint of easily suppressing the exotherm of the reaction, the surface treatment aspect 3 is preferable.

作為上述通式[4]所表示之矽氮烷化合物之具體例,例如可列舉:[(CH3 )3 Si]2 NH、[(CH3 )2 Si(H)]2 NH、[CH3 Si(H)2 ]2 NH、[C2 H5 Si(CH3 )2 ]2 NH、[(C2 H5 )2 Si(CH3 )]2 NH、[(C2 H5 )3 Si]2 NH、[C3 H7 Si(CH3 )2 ]2 NH、[(C3 H7 )2 Si(CH3 )]2 NH、[(C3 H7 )3 Si]2 NH、[C4 H9 Si(CH3 )2 ]2 NH、[C5 H11 Si(CH3 )2 ]2 NH、[C6 H13 Si(CH3 )2 ]2 NH、[C7 H15 Si(CH3 )2 ]2 NH、[C8 H17 Si(CH3 )2 ]2 NH、[C9 H19 Si(CH3 )2 ]2 NH、[C10 H21 Si(CH3 )2 ]2 NH、[C11 H23 Si(CH3 )2 ]2 NH、[C12 H25 Si(CH3 )2 ]2 NH、[C13 H27 Si(CH3 )2 ]2 NH、[C14 H29 Si(CH3 )2 ]2 NH、[C15 H31 Si(CH3 )2 ]2 NH、[C16 H33 Si(CH3 )2 ]2 NH、[C17 H35 Si(CH3 )2 ]2 NH、[C18 H37 Si(CH3 )2 ]2 NH、[(C2 H5 )2 Si(H)]2 NH、[C2 H5 Si(H)2 ]2 NH、[C2 H5 Si(CH3 )(H)]2 NH、[(C3 H7 )2 Si(H)]2 NH、[C3 H7 Si(H)2 ]2 NH、[CF3 CH2 CH2 Si(CH3 )2 ]2 NH、[C2 F5 CH2 CH2 Si(CH3 )2 ]2 NH、[C3 F7 CH2 CH2 Si(CH3 )2 ]2 NH、[C4 F9 CH2 CH2 Si(CH3 )2 ]2 NH、[C5 F11 CH2 CH2 Si(CH3 )2 ]2 NH、[C6 F13 CH2 CH2 Si(CH3 )2 ]2 NH、[C7 F15 CH2 CH2 Si(CH3 )2 ]2 NH、[C8 F17 CH2 CH2 Si(CH3 )2 ]2 NH、[CF3 CH2 CH2 Si(CH3 )(H)]2 NH等,其中,尤其以[(CH3 )3 Si]2 NH、[C2 H5 Si(CH3 )2 ]2 NH、[C3 H7 Si(CH3 )2 ]2 NH、[C4 H9 Si(CH3 )2 ]2 NH、[CF3 CH2 CH2 Si(CH3 )2 ]2 NH為佳,尤佳為[(CH3 )3 Si]2 NH。Specific examples of the silazane compound represented by the general formula [4] include: [(CH 3 ) 3 Si] 2 NH, [(CH 3 ) 2 Si(H)] 2 NH, [CH 3 Si(H) 2 ] 2 NH, [C 2 H 5 Si(CH 3 ) 2 ] 2 NH, [(C 2 H 5 ) 2 Si(CH 3 )] 2 NH, [(C 2 H 5 ) 3 Si ] 2 NH, [C 3 H 7 Si(CH 3 ) 2 ] 2 NH, [(C 3 H 7 ) 2 Si(CH 3 )] 2 NH, [(C 3 H 7 ) 3 Si] 2 NH, [ C 4 H 9 Si(CH 3 ) 2 ] 2 NH, [C 5 H 11 Si(CH 3 ) 2 ] 2 NH, [C 6 H 13 Si(CH 3 ) 2 ] 2 NH, [C 7 H 15 Si (CH 3 ) 2 ] 2 NH, [C 8 H 17 Si(CH 3 ) 2 ] 2 NH, [C 9 H 19 Si(CH 3 ) 2 ] 2 NH, [C 10 H 21 Si(CH 3 ) 2 ] 2 NH, [C 11 H 23 Si(CH 3 ) 2 ] 2 NH, [C 12 H 25 Si(CH 3 ) 2 ] 2 NH, [C 13 H 27 Si(CH 3 ) 2 ] 2 NH, [ C 14 H 29 Si(CH 3 ) 2 ] 2 NH, [C 15 H 31 Si(CH 3 ) 2 ] 2 NH, [C 16 H 33 Si(CH 3 ) 2 ] 2 NH, [C 17 H 35 Si (CH 3 ) 2 ] 2 NH, [C 18 H 37 Si(CH 3 ) 2 ] 2 NH, [(C 2 H 5 ) 2 Si(H)] 2 NH, [C 2 H 5 Si(H) 2 ] 2 NH, [C 2 H 5 Si(CH 3 )(H)] 2 NH, [(C 3 H 7 ) 2 Si(H)] 2 NH, [C 3 H 7 Si(H) 2 ] 2 NH , [CF 3 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH, [C 2 F 5 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH, [C 3 F 7 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH, [C 4 F 9 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH, [C 5 F 11 CH 2 CH 2 Si(C H 3 ) 2 ] 2 NH, [C 6 F 13 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH, [C 7 F 15 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH, [C 8 F 17 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH, [CF 3 CH 2 CH 2 Si(CH 3 )(H)] 2 NH, etc., among which, especially [(CH 3 ) 3 Si] 2 NH, [C 2 H 5 Si(CH 3 ) 2 ] 2 NH, [C 3 H 7 Si(CH 3 ) 2 ] 2 NH, [C 4 H 9 Si(CH 3 ) 2 ] 2 NH, [CF 3 CH 2 CH 2 Si(CH 3 ) 2 ] 2 NH is preferred, and [(CH 3 ) 3 Si] 2 NH is particularly preferred.

作為上述通式[6]所表示之酸性化合物之具體例,例如可列舉:HCl、HBr、HI、CF3 COOH、C2 F5 COOH、C3 F7 COOH、C4 F9 COOH、C5 F11 COOH、C6 F13 COOH、CF3 S(=O)2 OH、C2 F5 S(=O)2 OH、C3 F7 S(=O)2 OH、C4 F9 S(=O)2 OH、C5 F11 S(=O)2 OH、C6 F13 S(=O)2 OH、{CF3 S(=O)2 }2 NH、{C2 F5 S(=O)2 }2 NH、{C3 F7 S(=O)2 }2 NH、{C4 F9 S(=O)2 }2 NH、{C5 F11 S(=O)2 }2 NH、{C6 F13 S(=O)2 }2 NH、{CF3 S(=O)2 }3 CH、{C2 F5 S(=O)2 }3 CH、{C3 F7 S(=O)2 }3 CH、{C4 F9 S(=O)2 }3 CH、{C5 F11 S(=O)2 }3 CH、{C6 F13 S(=O)2 }3 CH等,其中,尤其以CF3 COOH、C2 F5 COOH、C3 F7 COOH、C4 F9 COOH為佳,尤佳為CF3 COOH。 實施例Specific examples of the acidic compound represented by the general formula [6] include, for example, HCl, HBr, HI, CF 3 COOH, C 2 F 5 COOH, C 3 F 7 COOH, C 4 F 9 COOH, and C 5 F 11 COOH, C 6 F 13 COOH, CF 3 S(=O) 2 OH, C 2 F 5 S(=O) 2 OH, C 3 F 7 S(=O) 2 OH, C 4 F 9 S( =O) 2 OH, C 5 F 11 S(=O) 2 OH, C 6 F 13 S(=O) 2 OH, {CF 3 S(=O) 2 } 2 NH, {C 2 F 5 S( =O) 2 } 2 NH, {C 3 F 7 S(=O) 2 } 2 NH, {C 4 F 9 S(=O) 2 } 2 NH, {C 5 F 11 S(=O) 2 } 2 NH, {C 6 F 13 S(=O) 2 } 2 NH, {CF 3 S(=O) 2 } 3 CH, {C 2 F 5 S(=O) 2 } 3 CH, {C 3 F 7 S(=O) 2 } 3 CH, {C 4 F 9 S(=O) 2 } 3 CH, {C 5 F 11 S(=O) 2 } 3 CH, {C 6 F 13 S(=O ) 2 } 3 CH, etc. Among them, CF 3 COOH, C 2 F 5 COOH, C 3 F 7 COOH, C 4 F 9 COOH are particularly preferred, and CF 3 COOH is particularly preferred. Example

以下,示出更具體地揭示本發明之實施形態之實施例。再者,本發明並不僅僅限定於該等實施例。Hereinafter, there will be shown an example that more specifically discloses the embodiment of the present invention. Furthermore, the present invention is not limited to these embodiments.

將晶圓之表面設為具有凹凸圖案之面、將保持於凹凸圖案之至少凹部之洗淨液替換為其他洗淨液之情況已於其他文獻等中進行過各種研究,為已經確立之技術,因此於本發明中,對利用撥水性保護膜形成用藥液對晶圓進行表面處理時之撥水性賦予效果進行評價。再者,於實施例中,作為評價接觸角時與晶圓表面接觸之液體,使用作為水系洗淨液之具有代表性之水。Setting the surface of the wafer as a surface with a concave-convex pattern, and replacing the cleaning solution holding at least the concave portion of the concave-convex pattern with another cleaning solution has been variously studied in other documents, and it is an established technology. Therefore, in the present invention, the effect of imparting water repellency when the wafer is surface-treated with the chemical solution for forming a water repellent protective film is evaluated. Furthermore, in the examples, as the liquid that contacts the wafer surface when evaluating the contact angle, water, which is a representative water-based cleaning liquid, was used.

然而,於表面具有凹凸圖案之晶圓之情形時,無法準確地評價形成於該凹凸圖案表面之撥水性保護膜本身之接觸角。However, in the case of a wafer with a concave-convex pattern on its surface, it is impossible to accurately evaluate the contact angle of the water-repellent protective film itself formed on the surface of the concave-convex pattern.

水滴之接觸角之評價係如亦記載於JIS R 3257「基板玻璃表面之潤濕性試驗方法」般,向樣品(基材)表面滴下數μl之水滴並藉由水滴與基材表面所成之角度之測定進行。然而,於具有圖案之晶圓之情形時,接觸角非常大。其原因在於,由於產生Wenzel效應或Cassie效應,且接觸角受基材之表面形狀(粗糙度)之影響,表觀上之水滴之接觸角增大。The evaluation of the contact angle of the water droplets is as described in JIS R 3257 "Test Method for Wettability of the Glass Surface of the Substrate". A few μl of water droplets are dropped on the surface of the sample (substrate) and formed by the water droplets and the substrate surface. The angle measurement is carried out. However, in the case of patterned wafers, the contact angle is very large. The reason is that due to the Wenzel effect or the Cassie effect, and the contact angle is affected by the surface shape (roughness) of the substrate, the apparent contact angle of the water droplets increases.

因此,於本實施例中,將上述藥液供於表面平滑之晶圓而於晶圓表面形成保護膜,並將該保護膜視為形成於表面形成有凹凸圖案之晶圓之表面之保護膜,從而進行各種評價。再者,於本實施例中,使用於表面平滑之矽晶圓上具有SiO2 層之「附SiO2 膜晶圓」作為表面平滑之晶圓。Therefore, in this embodiment, the above-mentioned chemical solution is applied to a wafer with a smooth surface to form a protective film on the surface of the wafer, and the protective film is regarded as a protective film formed on the surface of the wafer with a concave-convex pattern formed on the surface , In order to carry out various evaluations. Furthermore, in this embodiment, a "wafer with SiO 2 film" having an SiO 2 layer on a smooth surface silicon wafer is used as a smooth surface wafer.

將詳情記述於下文。以下,記載評價方法、撥水性保護膜形成用藥液或原料藥液之製備、使用撥水性保護膜形成用藥液之晶圓之表面處理方法、及評價結果。The details are described below. The following describes the evaluation method, the preparation of the water-repellent protective film formation chemical solution or raw material chemical liquid, the surface treatment method of the wafer using the water-repellent protective film formation chemical solution, and the evaluation results.

[評價方法]形成於晶圓表面之保護膜之接觸角評價(撥水性賦予效果之評價) 於形成有保護膜之晶圓表面上放置純水約2 μl,並利用接觸角計(協和界面科學製造:CA-X型)對水滴與晶圓表面所成之角(接觸角)進行測定,將80°以上設為合格。[Evaluation method] Contact angle evaluation of the protective film formed on the wafer surface (evaluation of the effect of imparting water repellency) Put about 2 μl of pure water on the surface of the wafer with the protective film, and measure the angle (contact angle) between the water drop and the wafer surface with a contact angle meter (manufactured by Kyowa Interface Science: CA-X type). Set 80° or more to pass.

[實施例1-1] (1-1)撥水性保護膜形成用藥液之製備 將作為(II)矽化合物之三氟乙酸三甲基矽烷酯[TMS-TFA:(CH3 )3 Si-OC(=O)CF3 ]:15 g、作為(IV)矽氮烷化合物之六甲基二矽氮烷[HMDS:(CH3 )3 Si-NH-Si(CH3 )3 ]:70 g、作為(III)非質子性溶劑之丙二醇單甲醚乙酸酯(PGMEA):915 g混合而獲得溶液狀態之原料藥液。其次,向原料藥液添加作為質子性化合物之水:3.6 g,藉此使相對於TMS-TFA、HMDS、PGMEA之總量1 kg為0.2莫耳之質子性化合物(液體狀態之水)與原料藥液接觸而製備撥水性保護膜形成用藥液。[Example 1-1] (1-1) Preparation of chemical solution for forming water-repellent protective film will be (II) trimethylsilyl trifluoroacetate as a silicon compound [TMS-TFA: (CH 3 ) 3 Si-OC (=O)CF 3 ]: 15 g, hexamethyldisilazane as (IV) silazane compound [HMDS: (CH 3 ) 3 Si-NH-Si(CH 3 ) 3 ]: 70 g, (III) Propylene glycol monomethyl ether acetate (PGMEA) as an aprotic solvent: 915 g was mixed to obtain a crude drug solution in a solution state. Secondly, add water as a protic compound to the bulk drug solution: 3.6 g, thereby making 0.2 mol of the protic compound (water in liquid state) and the raw material relative to the total of 1 kg of TMS-TFA, HMDS, and PGMEA The chemical solution is contacted to prepare a chemical solution for forming a water-repellent protective film.

(1-2)矽晶圓之洗淨 將平滑之附熱氧化膜矽晶圓(表面具有厚度1 μm之熱氧化膜層之Si晶圓)於室溫下於1質量%之氫氟酸水溶液中浸漬10分鐘,於室溫下於純水中浸漬1分鐘,並於室溫下於2-丙醇(iPA)中浸漬1分鐘。(1-2) Cleaning of silicon wafer A smooth silicon wafer with thermal oxide film (Si wafer with a thermal oxide film layer of 1 μm thick on the surface) is immersed in a 1% by mass hydrofluoric acid aqueous solution for 10 minutes at room temperature, Soak in water for 1 minute and immerse in 2-propanol (iPA) for 1 minute at room temperature.

(1-3)利用保護膜形成用藥液對矽晶圓表面進行之表面處理 將上述洗淨後之矽晶圓於25℃下於上述「(1-1)撥水性保護膜形成用藥液之製備」中製備之撥水性保護膜形成用藥液中浸漬30秒鐘,並於室溫下於iPA中浸漬30秒鐘。最後,將矽晶圓自iPA中取出,吹送空氣而去除表面之iPA,從而使矽晶圓乾燥。(1-3) Surface treatment of silicon wafer surface with protective film forming chemical solution The cleaned silicon wafer was immersed in the water-repellent protective film formation chemical solution prepared in the above "(1-1) Preparation of water-repellent protective film formation chemical solution" at 25°C for 30 seconds, and placed in the chamber Soak in iPA for 30 seconds at warm temperature. Finally, the silicon wafer is taken out from the iPA, and air is blown to remove the iPA on the surface, thereby drying the silicon wafer.

本實施例係利用表面處理態樣2之方法進行表面處理。對所獲得之晶圓進行評價,結果如表1所示,表面處理前之初始接觸角未達10°者之表面處理後之接觸角為90°,顯示優異之撥水性賦予效果。This embodiment uses the method of surface treatment mode 2 for surface treatment. The obtained wafers were evaluated, and the results are shown in Table 1. The initial contact angle before surface treatment was less than 10°, and the contact angle after surface treatment was 90°, showing an excellent water repellency imparting effect.

[表1]

Figure 108101088-A0304-0001
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 1]
Figure 108101088-A0304-0001
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例1-2~1-23] 變更實施例1-1中使用之質子性化合物之種類、接觸方法或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例1-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表1。 再者,表中,「iPA」係指2-丙醇,「MeOH」係指甲醇,「EtOH」係指乙醇,「nBuOH」係指1-丁醇,「PGME」係指丙二醇單甲醚,「TFAcA」係指三氟乙醯胺。[Examples 1-2~1-23] The type, contact method, or contact amount of the protic compound used in Example 1-1, and the type or content of aminosilane compound, silicon compound, or silazane compound were changed. Otherwise, the same as in Example 1-1 The surface treatment of the wafer was carried out in the same way, and then the evaluation was carried out. The results are shown in Table 1. Furthermore, in the table, "iPA" refers to 2-propanol, "MeOH" refers to methanol, "EtOH" refers to ethanol, "nBuOH" refers to 1-butanol, and "PGME" refers to propylene glycol monomethyl ether. "TFAcA" refers to trifluoroacetamide.

再者,於實施例1-18中,首先,將作為矽氮烷化合物之二丁基四甲基二矽氮烷[DBTMDS:C4 H9 (CH3 )2 Si-NH-Si(CH3 )2 C4 H9 ]:86 g、作為非質子性溶劑之PGMEA:900 g、三氟乙酸酐:14 g混合而藉由後述反應獲得溶液狀態之原料藥液。三氟乙酸酐立即與DBTMDS反應而變為三氟乙酸丁基二甲基矽烷酯[BDMS-TFA:C4 H9 (CH3 )2 Si-OC(=O)CF3 ]及丁基二甲基矽烷基三氟乙醯胺[BDS-TFAcA:C4 H9 (CH3 )2 Si-NH-C(=O)CF3 ]。即,本實施例之原料藥液之矽化合物或矽氮烷化合物之種類不同,並且含有BDS-TFAcA作為其他矽化合物。 其次,藉由向原料藥液添加作為質子性化合物之水:0.9 g而使相對於BDMS-TFA、DBTMDS、PGMEA之總量1 kg為0.05莫耳之質子性化合物(液體狀態之水)與原料藥液接觸,從而製備撥水性保護膜形成用藥液。Furthermore, in Examples 1-18, first, dibutyltetramethyldisilazane as a silazane compound [DBTMDS: C 4 H 9 (CH 3 ) 2 Si-NH-Si(CH 3 ) 2 C 4 H 9 ]: 86 g, PGMEA as an aprotic solvent: 900 g, and trifluoroacetic anhydride: 14 g are mixed to obtain a raw drug solution in a solution state by the reaction described below. Trifluoroacetic anhydride immediately reacts with DBTMDS to become butyldimethylsilyl trifluoroacetate [BDMS-TFA: C 4 H 9 (CH 3 ) 2 Si-OC(=O)CF 3 ] and butyl dimethyl Base silyl trifluoroacetamide [BDS-TFAcA: C 4 H 9 (CH 3 ) 2 Si-NH-C(=O)CF 3 ]. That is, the type of silicon compound or silazane compound of the bulk drug solution of this embodiment is different, and BDS-TFAcA is contained as other silicon compound. Secondly, by adding water as a protic compound to the crude drug solution: 0.9 g, the protic compound (water in liquid state) and the raw material are 0.05 mol relative to the total amount of BDMS-TFA, DBTMDS, and PGMEA 1 kg The chemical liquid is contacted to prepare a chemical liquid for forming a water-repellent protective film.

又,於實施例1-19中,首先,將作為矽氮烷化合物之二辛基四甲基二矽氮烷[DOTMDS:C8 H17 (CH3 )2 Si-NH-Si(CH3 )2 C8 H17 ]:89 g、作為非質子性溶劑之PGMEA:900 g、三氟乙酸酐:11 g混合而藉由後述反應獲得溶液狀態之原料藥液。三氟乙酸酐立即與DOTMDS反應而變為三氟乙酸辛基二甲基矽烷酯[ODMS-TFA:C8 H17 (CH3 )2 Si-OC(=O)CF3 ]及辛基二甲基矽烷基三氟乙醯胺[ODS-TFAcA:C8 H17 (CH3 )2 Si-NH-C(=O)CF3 ]。即,本實施例之原料藥液之矽化合物或矽氮烷化合物之種類不同,並且含有ODS-TFAcA作為其他矽化合物。 其次,藉由向原料藥液添加作為質子性化合物之水:0.9 g而使相對於ODMS-TFA、DOTMDS、PGMEA之總量1 kg為0.05莫耳之質子性化合物(液體狀態之水)與原料藥液接觸,從而製備撥水性保護膜形成用藥液。In addition, in Examples 1-19, first, dioctyltetramethyldisilazane [DOTMDS: C 8 H 17 (CH 3 ) 2 Si-NH-Si(CH 3 ) as a silazane compound 2 C 8 H 17 ]: 89 g, PGMEA as an aprotic solvent: 900 g, and trifluoroacetic anhydride: 11 g are mixed to obtain a raw drug solution in a solution state by the reaction described later. Trifluoroacetic anhydride immediately reacts with DOTMDS to become octyldimethylsilyl trifluoroacetate [ODMS-TFA: C 8 H 17 (CH 3 ) 2 Si-OC(=O)CF 3 ] and octyldimethylsilyl Trifluoroacetamide [ODS-TFAcA: C 8 H 17 (CH 3 ) 2 Si-NH-C(=O)CF 3 ]. That is, the type of silicon compound or silazane compound in the bulk drug solution of this embodiment is different, and ODS-TFAcA is contained as other silicon compound. Secondly, by adding water as a protic compound to the bulk drug solution: 0.9 g, the protic compound (water in liquid state) and the raw material are 0.05 mol relative to 1 kg of the total of ODMS-TFA, DOTMDS, and PGMEA. The chemical liquid is contacted to prepare a chemical liquid for forming a water-repellent protective film.

又,於實施例1-22中,首先,將作為矽氮烷化合物之HMDS:83 g、作為非質子性溶劑之PGMEA:900 g、三氟乙酸酐:17 g混合而藉由後述反應獲得溶液狀態之原料藥液。三氟乙酸酐立即與HMDS反應而變為TMS-TFA及三甲基矽烷基三氟乙醯胺[TMS-TFAcA:(CH3 )3 Si-NH-C(=O)CF3 ]。即,本實施例之原料藥液含有TMS-TFAcA作為除矽化合物或矽氮烷化合物以外之其他矽化合物。Also, in Example 1-22, first, HMDS as a silazane compound: 83 g, PGMEA as an aprotic solvent: 900 g, and trifluoroacetic anhydride: 17 g were mixed to obtain a solution by the reaction described below The raw material liquid in the state. Trifluoroacetic anhydride immediately reacts with HMDS to become TMS-TFA and trimethylsilyl trifluoroacetamide [TMS-TFAcA: (CH 3 ) 3 Si-NH-C(=O)CF 3 ]. That is, the bulk drug solution of this embodiment contains TMS-TFAcA as a silicon compound other than a silicon compound or a silazane compound.

再者,於實施例1-20、1-21、1-23中,以質子性化合物濃度相對於(II)、(III)、(IV)之總量1 kg未達0.001莫耳之比率將原料藥液載置於預先控制之空間內,並將特定量之氣體狀態之質子性化合物導入該空間使兩者接觸,藉此製備撥水性保護膜形成用藥液。Furthermore, in Examples 1-20, 1-21, 1-23, the ratio of the protic compound concentration to the total amount of (II), (III), (IV) 1 kg less than 0.001 mol The crude drug liquid is placed in a pre-controlled space, and a specific amount of gaseous protic compound is introduced into the space to make the two contact, thereby preparing a water-repellent protective film forming drug solution.

於任一實施例中,表面處理前之初始接觸角未達10°者於表面處理後接觸角均為80°以上,顯示優異之撥水性賦予效果。In any embodiment, the initial contact angle before the surface treatment is less than 10°, and the contact angle after the surface treatment is 80° or more, showing an excellent water repellency imparting effect.

[比較例1-1~1-3] 變更實施例1-1中使用之質子性化合物之種類或接觸量,除此以外,以與實施例1-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表1。表面處理後之接觸角均未達80°,撥水性賦予效果較實施例差。[Comparative Examples 1-1 to 1-3] Except that the type or contact amount of the protic compound used in Example 1-1 was changed, the surface treatment of the wafer was performed in the same manner as in Example 1-1, and the evaluation was performed. The results are shown in Table 1. The contact angle after surface treatment did not reach 80°, and the effect of imparting water repellency was worse than that of the examples.

根據實施例1-1~1-3、比較例1-1、1-2之結果,將相對於質子性化合物(液體狀態之水)之接觸量之表面處理後之接觸角之圖表示於圖7,將相對於(I)~(III)之總量中之(I)胺基矽烷化合物(TMS-NH2 )之含量之表面處理後之接觸角之圖表示於圖8。 根據圖7、8,於不接觸質子性化合物(液體狀態之水)之比較例1-1、或該接觸量過多之比較例1-2中,(I)~(III)之總量中之(I)胺基矽烷化合物(TMS-NH2 )之含量均過少(偏離相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之範圍),因此表面處理後之接觸角未達80°。 與此相對,藉由接觸質子性化合物(液體狀態之水),使用相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液之實施例1-1~1-3中,表面處理後之接觸角均超過80°,顯示更優異之撥水性賦予效果。Based on the results of Examples 1-1 to 1-3 and Comparative Examples 1-1 and 1-2, the contact angle after surface treatment relative to the contact amount of the protic compound (water in liquid state) is shown in the figure 7. The contact angle after surface treatment relative to the content of (I) aminosilane compound (TMS-NH 2 ) in the total amount of (I) to (III) is shown in FIG. 8. According to Figures 7 and 8, in Comparative Example 1-1 where the protic compound (water in liquid state) is not exposed, or Comparative Example 1-2 where the contact amount is too much, the total amount of (I) to (III) (I) The content of aminosilane compound (TMS-NH 2 ) is too small (the content of (I) deviates from the range of 0.02 to 0.5 mass% relative to the total amount of (I) to (III)), so surface treatment The subsequent contact angle did not reach 80°. On the other hand, by contacting the protic compound (liquid state water), a water-repellent protective film formation chemical solution with a content of (I) of 0.02 to 0.5 mass% relative to the total amount of (I) to (III) is used In Examples 1-1 to 1-3, the contact angles after surface treatment all exceeded 80°, showing a more excellent water repellency imparting effect.

又,於改變質子性化合物之種類之情形時亦確認到相同之傾向。 根據實施例1-4~1-6、比較例1-1、1-3之結果,將相對於質子性化合物(液體狀態之iPA)之接觸量之表面處理後之接觸角之圖表示於圖9,將相對於(I)~(III)之總量中之(I)胺基矽烷化合物(TMS-NH2 )之含量之表面處理後之接觸角之圖表示於圖10。 根據圖9、10,於不接觸質子性化合物(液體狀態之iPA)之比較例1-1、或該接觸量過多之比較例1-3中,(I)~(III)之總量中之(I)胺基矽烷化合物(TMS-NH2 )之含量均過少(偏離相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之範圍),因此表面處理後之接觸角未達80°。 與此相對,藉由接觸質子性化合物(液體狀態之iPA),使用相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液之實施例1-4~1-6中,表面處理後之接觸角均未超過80°,顯示更優異之撥水性賦予效果。In addition, the same tendency was confirmed when the types of protic compounds were changed. According to the results of Examples 1-4 to 1-6, and Comparative Examples 1-1, 1-3, the contact angle after surface treatment relative to the contact amount of the protic compound (iPA in liquid state) is shown in the figure 9. The contact angle after surface treatment with respect to the content of (I) aminosilane compound (TMS-NH 2 ) in the total amount of (I) to (III) is shown in FIG. 10. According to Figures 9 and 10, in Comparative Example 1-1 without contact with protic compounds (iPA in liquid state), or Comparative Example 1-3 with too much contact, among the total amount of (I) to (III) (I) The content of aminosilane compound (TMS-NH 2 ) is too small (the content of (I) deviates from the range of 0.02 to 0.5 mass% relative to the total amount of (I) to (III)), so surface treatment The subsequent contact angle did not reach 80°. In contrast, by contacting with protic compounds (iPA in liquid state), a chemical solution for forming a water-repellent protective film with a content of (I) of 0.02 to 0.5% by mass relative to the total amount of (I) to (III) is used In Examples 1-4 to 1-6, the contact angle after surface treatment did not exceed 80°, showing a more excellent water repellency imparting effect.

[實施例2-1] (2-1)原料藥液之製備 將作為(II)矽化合物之TMS-TFA:15 g、作為(IV)矽氮烷化合物之HMDS:70 g、作為(III)非質子性溶劑之PGMEA:915 g混合而獲得溶液狀態之原料藥液。[Example 2-1] (2-1) Preparation of API liquid Mix TMS-TFA as (II) silicon compound: 15 g, HMDS as (IV) silazane compound: 70 g, and PGMEA as (III) aprotic solvent: 915 g to obtain a solution state API liquid.

(2-2)撥水性保護膜形成用藥液之製備及利用保護膜形成用藥液對矽晶圓表面進行之表面處理 將以與實施例1-1相同之方法洗淨之矽晶圓浸漬於上述「(2-1)原料藥液之製備」中製備之原料藥液,繼而向該原料藥液添加作為質子性化合物之液體狀態之水:3.6 g,藉此使相對於TMS-TFA、HMDS、PGMEA之總量1 kg為0.2莫耳之質子性化合物(液體狀態之水)與原料藥液接觸而製備撥水性保護膜形成用藥液。於該撥水性保護膜形成用藥液浸漬30秒後將矽晶圓取出,並於室溫下於iPA中浸漬30秒,隨後將矽晶圓自iPA取出,吹送空氣而去除表面之iPA,使矽晶圓乾燥。(2-2) Preparation of water-repellent protective film forming chemical solution and surface treatment of silicon wafer surface using protective film forming chemical solution The silicon wafer cleaned by the same method as in Example 1-1 was immersed in the bulk drug solution prepared in the above "(2-1) Preparation of bulk drug solution", and then the bulk drug solution was added as a protic compound Water in liquid state: 3.6 g, by which a protic compound (water in liquid state) of 0.2 mol relative to the total amount of 1 kg of TMS-TFA, HMDS, and PGMEA is brought into contact with the crude drug solution to prepare water repellent protection Membrane formation liquid. After immersing in the water-repellent protective film formation chemical for 30 seconds, the silicon wafer was taken out, and then immersed in iPA for 30 seconds at room temperature. Then the silicon wafer was taken out from the iPA, and air was blown to remove the iPA on the surface to make the silicon The wafer is dry.

本實施例係利用表面處理態樣3之方法進行表面處理。對所獲得之晶圓進行評價,結果如表2所示,表面處理前之初始接觸角未達10°者之表面處理後之接觸角為90°,顯示優異之撥水性賦予效果。This embodiment uses the method of surface treatment mode 3 for surface treatment. The obtained wafers were evaluated, and the results are shown in Table 2. The initial contact angle before surface treatment was less than 10°, and the contact angle after surface treatment was 90°, showing an excellent water repellency imparting effect.

[表2]

Figure 108101088-A0304-0002
﹡胺基矽烷化合物之含量係相對於(I)~(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 2]
Figure 108101088-A0304-0002
﹡The content of aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例2-2~2-16] 變更實施例2-1中使用之質子性化合物之種類、接觸方法或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例2-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表2。[Examples 2-2~2-16] The type, contact method, or contact amount of the protic compound used in Example 2-1, and the type or content of aminosilane compound, silicon compound, or silazane compound were changed. Otherwise, the same as in Example 2-1 The surface treatment of the wafer was carried out in the same way, and then the evaluation was carried out. The results are shown in Table 2.

再者,於實施例2-13、2-14、2-16中,將利用與實施例1-1相同之方法洗淨之矽晶圓載置於預先導入有特定量之氣體狀態之質子性化合物之空間內,且於該矽晶圓表面(SiO2 膜側表面)盛裝原料藥液,藉此使原料藥液與質子性化合物接觸而製備撥水性保護膜形成用藥液。Furthermore, in Examples 2-13, 2-14, and 2-16, the silicon wafers cleaned by the same method as in Example 1-1 were placed on the protic compound introduced in advance in a specific amount of gaseous state In the space, and on the surface of the silicon wafer (the side surface of the SiO 2 film), the raw material liquid is filled, so that the raw material liquid is brought into contact with the protic compound to prepare the water-repellent protective film forming liquid.

於任一實施例中,表面處理前之初始接觸角未達10°者於表面處理後接觸角均為80°以上,顯示優異之撥水性賦予效果。In any embodiment, the initial contact angle before the surface treatment is less than 10°, and the contact angle after the surface treatment is 80° or more, showing an excellent water repellency imparting effect.

[比較例2-1~2-3] 變更實施例2-1中使用之質子性化合物之種類或接觸量,除此以外,以與實施例2-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表2。表面處理後之接觸角均未達80°,撥水性賦予效果較實施例差。[Comparative Examples 2-1 to 2-3] Except for changing the type or contact amount of the protic compound used in Example 2-1, the surface treatment of the wafer was performed in the same manner as in Example 2-1, and the evaluation was performed. The results are shown in Table 2. The contact angle after surface treatment did not reach 80°, and the effect of imparting water repellency was worse than that of the examples.

[實施例3-1] 將作為(IV)矽氮烷化合物之HMDS:71 g、作為(III)非質子性溶劑之PGMEA:929 g混合而獲得溶液狀態之原料藥液。其次,藉由向原料藥液添加作為酸性化合物之三氟乙酸[TFA:CF3 COOH]:22.8 g而使相對於HMDS、PGMEA之總量1 kg為0.2莫耳之酸性化合物(液體狀態之TFA)與原料藥液接觸,從而製備撥水性保護膜形成用藥液。除此以外,以與實施例1-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表3。[Example 3-1] HMDS as (IV) silazane compound: 71 g, and PGMEA as (III) aprotic solvent: 929 g were mixed to obtain a raw drug solution in a solution state. Secondly, by adding trifluoroacetic acid [TFA: CF 3 COOH]: 22.8 g as an acidic compound to the crude drug solution, the acidic compound (TFA in liquid state) is 0.2 mol relative to the total amount of HMDS and PGMEA 1 kg. ) Contact with the raw chemical liquid to prepare a chemical liquid for forming a water-repellent protective film. Except for this, the surface treatment of the wafer was performed in the same manner as in Example 1-1, and the evaluation was further performed. The results are shown in Table 3.

本實施例係利用表面處理態樣4之方法進行過表面處理者。對所獲得之晶圓進行評價,結果如表3所示,表面處理前之初始接觸角未達10°者之表面處理後之接觸角為90°,顯示優異之撥水性賦予效果。In this embodiment, the surface treatment has been performed by the method of surface treatment mode 4. The obtained wafers were evaluated, and the results are shown in Table 3. The contact angle after the surface treatment of those whose initial contact angle before surface treatment was less than 10° was 90°, showing excellent water repellency imparting effect.

[表3]

Figure 108101088-A0304-0003
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[table 3]
Figure 108101088-A0304-0003
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例3-2~3-6] 變更實施例3-1中使用之酸性化合物之種類或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例3-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表3。 再者,表中,「TFMSA」係指三氟甲磺酸[CF3 SO3 H],「TMS-TFMSA」係指三氟甲磺酸三甲基矽烷酯[(CH3 )3 Si-OS(=O)2 CF3 ]。[Examples 3-2 to 3-6] In addition to changing the type or contact amount of acidic compound used in Example 3-1, and the type or content of aminosilane compound, silicon compound or silazane compound, The surface treatment of the wafer was performed in the same manner as in Example 3-1, and the evaluation was performed. The results are shown in Table 3. Furthermore, in the table, "TFMSA" refers to trifluoromethanesulfonic acid [CF 3 SO 3 H], and "TMS-TFMSA" refers to trimethylsilyl trifluoromethanesulfonate [(CH 3 ) 3 Si-OS (=O) 2 CF 3 ].

於任一實施例中,表面處理前之初始接觸角未達10°者於表面處理後接觸角均為80°以上,顯示優異之撥水性賦予效果。In any embodiment, the initial contact angle before the surface treatment is less than 10°, and the contact angle after the surface treatment is 80° or more, showing an excellent water repellency imparting effect.

[比較例3-1、3-2] 變更實施例3-1中使用之酸性化合物之接觸量,除此以外,以與實施例3-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表3。表面處理後之接觸角均未達80°,撥水性賦予效果較實施例差。[Comparative Examples 3-1, 3-2] Except for changing the contact amount of the acidic compound used in Example 3-1, the surface treatment of the wafer was performed in the same manner as in Example 3-1, and the evaluation was performed. The results are shown in Table 3. The contact angle after surface treatment did not reach 80°, and the effect of imparting water repellency was worse than that of the examples.

[實施例4-1] (4-1)原料藥液之製備 將作為(IV)矽氮烷化合物之HMDS:71 g、作為(III)非質子性溶劑之PGMEA:929 g混合而獲得溶液狀態之原料藥液。[Example 4-1] (4-1) Preparation of API liquid Mix HMDS as (IV) silazane compound: 71 g, and PGMEA as (III) aprotic solvent: 929 g to obtain a raw drug solution in a solution state.

(4-2)撥水性保護膜形成用藥液之製備及利用保護膜形成用藥液對矽晶圓表面進行之表面處理 將利用與實施例1-1相同之方法洗淨之矽晶圓浸漬於上述「(4-1)原料藥液之製備」中製備之原料藥液,繼而,向該原料藥液添加作為酸性化合物之液體狀態之TFA:22.8 g,藉此使相對於HMDS、PGMEA之總量1 kg為0.2莫耳之酸性化合物(液體狀態之TFA)接觸原料藥液,從而製備撥水性保護膜形成用藥液。於該撥水性保護膜形成用藥液浸漬30秒後將矽晶圓取出,於室溫下於iPA浸漬30秒,隨後將矽晶圓自iPA取出,吹送空氣而去除表面之iPA,從而使矽晶圓乾燥。(4-2) Preparation of water-repellent protective film formation chemical solution and surface treatment of silicon wafer surface using protective film formation chemical solution The silicon wafers cleaned by the same method as in Example 1-1 were immersed in the bulk drug solution prepared in the above "(4-1) Preparation of bulk drug solution", and then added to the bulk drug solution as an acid compound Liquid TFA: 22.8 g, so that 0.2 mol of acidic compound (TFA in liquid state) relative to the total amount of HMDS and PGMEA 1 kg is brought into contact with the raw drug solution to prepare a water-repellent protective film formation drug solution. After being immersed in the water-repellent protective film formation chemical for 30 seconds, the silicon wafer was taken out, and then immersed in iPA for 30 seconds at room temperature. Then the silicon wafer was taken out of the iPA, and air was blown to remove the iPA on the surface, thereby making the silicon crystal Round dry.

本實施例係利用表面處理態樣5之方法進行表面處理。對所獲得之晶圓進行評價,結果如表4所示,表面處理前之初始接觸角未達10°之表面處理後之接觸角為90°,顯示優異之撥水性賦予效果。This embodiment uses the method of surface treatment mode 5 for surface treatment. The obtained wafers were evaluated, and the results are shown in Table 4. The contact angle after surface treatment with the initial contact angle before surface treatment less than 10° was 90°, showing excellent water repellency imparting effect.

[表4]

Figure 108101088-A0304-0004
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 4]
Figure 108101088-A0304-0004
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例4-2~4-6] 變更實施例4-1中使用之酸性化合物之種類或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例4-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表4。[Examples 4-2 to 4-6] The type or contact amount of acidic compound used in Example 4-1, and the type or content of aminosilane compound, silicon compound, or silazane compound were changed, except that it was performed in the same manner as in Example 4-1. The surface treatment of the wafer, and then the evaluation. The results are shown in Table 4.

於任一實施例中,表面處理前之初始接觸角未達10°者於表面處理後接觸角均為80°以上,顯示優異之撥水性賦予效果。In any embodiment, the initial contact angle before the surface treatment is less than 10°, and the contact angle after the surface treatment is 80° or more, showing an excellent water repellency imparting effect.

[比較例4-1、4-2] 變更實施例4-1中使用之酸性化合物之接觸量,除此以外,以與實施例4-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表4。表面處理後之接觸角均未達80°,撥水性賦予效果較實施例差。[Comparative Examples 4-1, 4-2] Except for changing the contact amount of the acidic compound used in Example 4-1, the surface treatment of the wafer was performed in the same manner as in Example 4-1, and the evaluation was performed. The results are shown in Table 4. The contact angle after surface treatment did not reach 80°, and the effect of imparting water repellency was worse than that of the examples.

如上所述,即便為不同之表面處理態樣,藉由採用本發明之撥水性保護膜形成用藥液、及本發明之晶圓之表面處理方法,可較先前進一步提高撥水性賦予效果。As described above, even with different surface treatments, the water-repellent protective film forming chemical solution of the present invention and the wafer surface treatment method of the present invention can further improve the effect of imparting water-repellent properties.

[實施例1-1a] 於「撥水性保護膜形成用藥液之製備」中,將作為質子性化合物之水以稀釋於作為非質子性溶劑之PGMEA之狀態(於不相溶之情形時為分散之狀態)添加至原料藥液,除此以外,進行與實施例1-1相同之操作,且進行相同之評價。再者,水之添加量相對於TMS-TFA、HMDS、原料藥液所包含之PGMEA、及稀釋所使用之PGMEA之總量1 kg為0.2莫耳。將結果示於表5。再者,使稀釋所使用之PGMEA之量與原料藥液所包含之PGMEA之量相同。[Example 1-1a] In the "preparation of a chemical solution for forming a water-repellent protective film", water as a protic compound is added to the drug substance in a state that it is diluted with PGMEA as an aprotic solvent (in the case of incompatible conditions, it is dispersed) Except for this, the same operation as in Example 1-1 was performed, and the same evaluation was performed. Furthermore, the amount of water added is 0.2 mol relative to the total amount of 1 kg of TMS-TFA, HMDS, PGMEA contained in the bulk drug solution, and PGMEA used for dilution. The results are shown in Table 5. Furthermore, the amount of PGMEA used for dilution is the same as the amount of PGMEA contained in the bulk drug solution.

[表5]

Figure 108101088-A0304-0005
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[table 5]
Figure 108101088-A0304-0005
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例1-2a~1-22a、比較例1-2a~1-3a] 變更實施例1-1a中使用之質子性化合物之種類、接觸方法或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例1-1a相同之方式進行晶圓之表面處理,進而進行其評價。再者,對於實施例1-20a、1-21a,將氣體狀態之質子性化合物稀釋於氣體狀態之非質子性溶劑而使之與原料藥液接觸。將結果示於表5。 再者,對於不接觸質子性化合物之比較例,記載比較例1-1之結果。[Examples 1-2a to 1-22a, Comparative Examples 1-2a to 1-3a] The type, contact method or contact amount of the protic compound used in Example 1-1a, and the type or content of aminosilane compound, silicon compound, or silazane compound were changed. Otherwise, the same as in Example 1-1a The surface treatment of the wafer was carried out in the same way, and then the evaluation was carried out. Furthermore, for Examples 1-20a and 1-21a, the protic compound in the gaseous state was diluted in the aprotic solvent in the gaseous state to make it contact with the crude drug solution. The results are shown in Table 5. In addition, the results of Comparative Example 1-1 are described for comparative examples that are not exposed to protic compounds.

[實施例2-1a] 於「撥水性保護膜形成用藥液之製備及利用保護膜形成用藥液對矽晶圓表面進行之表面處理」中,將作為質子性化合物之水以稀釋於作為非質子性溶劑之PGMEA之狀態(於不相溶之情形時為分散之狀態)添加至原料藥液,除此以外,進行與實施例2-1相同之操作,且進行相同之評價。再者,水之添加量相對於TMS-TFA、HMDS、原料藥液所包含之PGMEA、及稀釋所使用之PGMEA之總量1 kg為0.2莫耳。將結果示於表6。再者,使稀釋所使用之PGMEA之量與原料藥液所包含之PGMEA之量相同。[Example 2-1a] In "Preparation of the chemical solution for forming a water-repellent protective film and surface treatment of the surface of a silicon wafer with the chemical solution for forming a protective film", water as a protic compound is diluted in the state of PGMEA as an aprotic solvent ( In the case of incompatibility, it is in a dispersed state) was added to the bulk drug solution, except that the same operation as in Example 2-1 was performed, and the same evaluation was performed. Furthermore, the amount of water added is 0.2 mol relative to the total amount of 1 kg of TMS-TFA, HMDS, PGMEA contained in the bulk drug solution, and PGMEA used for dilution. The results are shown in Table 6. Furthermore, the amount of PGMEA used for dilution is the same as the amount of PGMEA contained in the bulk drug solution.

[表6]

Figure 108101088-A0304-0006
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 6]
Figure 108101088-A0304-0006
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例2-2a~2-15a、比較例2-2a~2-3a] 變更實施例2-1a中使用之質子性化合物之種類、接觸方法或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例2-1a相同之方式進行晶圓之表面處理,進而進行其評價。再者,對於實施例2-13a、2-14a,將氣體狀態之質子性化合物稀釋於氣體狀態之非質子性溶劑而使之與原料藥液接觸。將結果示於表6。 再者,對於不接觸質子性化合物之比較例,記載比較例2-1之結果。[Examples 2-2a to 2-15a, Comparative Examples 2-2a to 2-3a] The type, contact method, or contact amount of the protic compound used in Example 2-1a, and the type or content of aminosilane compound, silicon compound, or silazane compound were changed. Otherwise, the same as in Example 2-1a The surface treatment of the wafer was carried out in the same way, and then the evaluation was carried out. Furthermore, for Examples 2-13a and 2-14a, the protic compound in the gaseous state was diluted in the aprotic solvent in the gaseous state and brought into contact with the crude drug solution. The results are shown in Table 6. In addition, the results of Comparative Example 2-1 are described for comparative examples that are not exposed to protic compounds.

[實施例3-1a] 於「撥水性保護膜形成用藥液之製備」中,將作為酸性化合物之TFA以稀釋於作為非質子性溶劑之PGMEA之狀態(於不相溶之情形時為分散之狀態)添加至原料藥液,除此以外,進行與實施例3-1相同之操作,且進行相同之評價。再者,TFA之添加量相對於HMDS、原料藥液所包含之PGMEA、及稀釋所使用之PGMEA之總量1 kg為0.2莫耳。將結果示於表7。再者,使稀釋所使用之PGMEA之量與原料藥液所包含之PGMEA之量相同。[Example 3-1a] In the "Preparation of the chemical solution for forming a water-repellent protective film", add TFA as an acidic compound in a state of being diluted with PGMEA as an aprotic solvent (in a dispersed state when it is incompatible), and add it to the raw drug solution Except for this, the same operation as in Example 3-1 was performed, and the same evaluation was performed. Furthermore, the added amount of TFA is 0.2 mol relative to the total 1 kg of HMDS, PGMEA contained in the bulk drug solution, and PGMEA used for dilution. The results are shown in Table 7. Furthermore, the amount of PGMEA used for dilution is the same as the amount of PGMEA contained in the bulk drug solution.

[表7]

Figure 108101088-A0304-0007
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 7]
Figure 108101088-A0304-0007
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例3-2a~3-6a、比較例3-2a] 變更實施例3-1a中使用之酸性化合物之種類或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例3-1a相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表7。 再者,關於不接觸酸性化合物之比較例,記載比較例3-1之結果。[Examples 3-2a to 3-6a, Comparative Example 3-2a] The type or contact amount of acidic compound used in Example 3-1a, and the type or content of aminosilane compound, silicon compound, or silazane compound were changed, except that it was performed in the same manner as in Example 3-1a The surface treatment of the wafer, and then the evaluation. The results are shown in Table 7. In addition, the results of Comparative Example 3-1 are described for comparative examples that are not exposed to acidic compounds.

[實施例4-1a] 於「撥水性保護膜形成用藥液之製備及利用保護膜形成用藥液對矽晶圓表面進行之表面處理」中,將作為酸性化合物之TFA以稀釋於作為非質子性溶劑之PGMEA之狀態(於不相溶之情形時為分散之狀態)添加至原料藥液,除此以外,進行與實施例4-1相同之操作,且進行相同之評價。再者,TFA之添加量相對於HMDS、原料藥液所包含之PGMEA、及稀釋所使用之PGMEA之總量1 kg為0.2莫耳。將結果示於表8。再者,使稀釋所使用之PGMEA之量與原料藥液所包含之PGMEA之量相同。[Example 4-1a] In "Preparation of water-repellent protective film forming chemical solution and surface treatment of silicon wafer surface using protective film forming chemical solution", TFA as an acid compound is diluted in the state of PGMEA as an aprotic solvent (in In the case of immiscibility, it is in a dispersed state) was added to the bulk drug solution, except that the same operation as in Example 4-1 was performed, and the same evaluation was performed. Furthermore, the added amount of TFA is 0.2 mol relative to the total 1 kg of HMDS, PGMEA contained in the bulk drug solution, and PGMEA used for dilution. The results are shown in Table 8. Furthermore, the amount of PGMEA used for dilution is the same as the amount of PGMEA contained in the bulk drug solution.

[表8]

Figure 108101088-A0304-0008
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 8]
Figure 108101088-A0304-0008
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例4-2a~4-6a、比較例4-2a] 變更實施例4-1a中使用之酸性化合物之種類或接觸量、及胺基矽烷化合物、矽化合物或矽氮烷化合物之種類或含量,除此以外,以與實施例4-1a相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表8。 再者,關於不接觸酸性化合物之比較例,記載比較例4-1之結果。[Examples 4-2a to 4-6a, Comparative Example 4-2a] The type or contact amount of acidic compound used in Example 4-1a, and the type or content of aminosilane compound, silicon compound or silazane compound were changed, except that the same procedure as in Example 4-1a was performed. The surface treatment of the wafer, and then the evaluation. The results are shown in Table 8. In addition, the results of Comparative Example 4-1 are described for comparative examples that are not exposed to acidic compounds.

[實施例5-1] 於「撥水性保護膜形成用藥液之製備」中,將質子性化合物設為NH3 並以稀釋於作為非質子性溶劑之二㗁烷之狀態添加至原料藥液,除此以外,進行與實施例1-2相同之操作,且進行相同之評價。再者,NH3 之添加量相對於TMS-TFA、HMDS、原料藥液所包含之PGMEA、及稀釋所使用之二㗁烷之總量1 kg為0.05莫耳。將結果示於表9。再者,添加至原料藥液時之NH3 /二㗁烷溶液之濃度係設為0.4莫耳/升。[Example 5-1] In "Preparation of a chemical solution for forming a water-repellent protective film", the protic compound was set to NH 3 and added to the raw chemical solution in a state of being diluted in dioxane as an aprotic solvent, Otherwise, the same operation as in Example 1-2 was performed, and the same evaluation was performed. Furthermore, the addition amount of NH 3 is 0.05 mol relative to 1 kg of the total amount of TMS-TFA, HMDS, PGMEA contained in the bulk drug solution, and dioxane used for dilution. The results are shown in Table 9. Furthermore, the concentration of the NH 3 /dioxane solution when added to the bulk drug solution is set to 0.4 mol/liter.

[表9]

Figure 108101088-A0304-0009
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 9]
Figure 108101088-A0304-0009
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例5-2] 將實施例5-1中稀釋所使用之非質子性溶劑之種類變更為四氫呋喃[THF],除此以外,以與實施例5-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表9。 再者,關於不接觸質子性化合物之比較例,記載比較例1-1之結果。[Example 5-2] Except that the type of aprotic solvent used for dilution in Example 5-1 was changed to tetrahydrofuran [THF], the surface treatment of the wafer was performed in the same manner as in Example 5-1, and the evaluation was performed. The results are shown in Table 9. In addition, regarding the comparative example not exposed to the protic compound, the result of the comparative example 1-1 is described.

[實施例6-1] 於「撥水性保護膜形成用藥液之製備及利用保護膜形成用藥液對矽晶圓表面進行之表面處理」中,將質子性化合物設為NH3 且以稀釋於作為非質子性溶劑之二㗁烷之狀態添加至原料藥液,除此以外,進行與實施例2-2相同之操作,且進行相同之評價。再者,NH3 之添加量相對於TMS-TFA、HMDS、原料藥液所包含之PGMEA、及稀釋所使用之二㗁烷之總量1 kg為0.05莫耳。將結果示於表10。再者,添加至原料藥液時之NH3 /二㗁烷溶液之濃度係設為0.4莫耳/升。[Example 6-1] In "Preparation of a chemical solution for forming a water-repellent protective film and surface treatment of a silicon wafer surface using a chemical solution for forming a protective film", the protic compound was set to NH 3 and diluted in The aprotic solvent, dioxane, was added to the raw drug solution in the state of addition, and the same operation as in Example 2-2 was performed, and the same evaluation was performed except that. Furthermore, the addition amount of NH 3 is 0.05 mol relative to 1 kg of the total amount of TMS-TFA, HMDS, PGMEA contained in the bulk drug solution, and dioxane used for dilution. The results are shown in Table 10. Furthermore, the concentration of the NH 3 /dioxane solution when added to the bulk drug solution is set to 0.4 mol/liter.

[表10]

Figure 108101088-A0304-0010
﹡胺基矽烷化合物之含量係相對於(I)〜(III)之總量。其他成分之含量係相對於撥水性保護膜形成用藥液之總量。[Table 10]
Figure 108101088-A0304-0010
*The content of the aminosilane compound is relative to the total amount of (I) ~ (III). The content of other components is relative to the total amount of the liquid medicine for forming the water-repellent protective film.

[實施例6-2] 將實施例6-1中稀釋所使用之非質子性溶劑之種類變更為四氫呋喃[THF],除此以外,以與實施例6-1相同之方式進行晶圓之表面處理,進而進行其評價。將結果示於表10。 再者,關於不接觸質子性化合物之比較例,記載比較例2-1之結果。[Example 6-2] Except that the type of aprotic solvent used for dilution in Example 6-1 was changed to tetrahydrofuran [THF], the surface treatment of the wafer was performed in the same manner as in Example 6-1, and the evaluation was performed. The results are shown in Table 10. In addition, the results of Comparative Example 2-1 are described for comparative examples that do not contact the protic compound.

如上所述,即便添加至原料藥液之質子性化合物或酸性化合物為稀釋於非質子性溶劑之狀態(於不相溶之情形時為分散之狀態),亦可同樣地較先前進一步提高撥水性賦予效果。As mentioned above, even if the protic compound or acidic compound added to the bulk drug solution is diluted in an aprotic solvent (in the case of incompatible conditions, it is in a dispersed state), the water repellency can be further improved than before. Give effect.

圖1係表面處理態樣1之流程圖。 圖2係表面處理態樣2之流程圖。 圖3係表面處理態樣3之流程圖。 圖4係表面處理態樣4之流程圖。 圖5係表面處理態樣5之流程圖。 圖6係表面處理態樣6之流程圖。 圖7係相對於水添加量之表面處理後之接觸角之圖表(比較例1-1、實施例1-3、實施例1-2、實施例1-1、比較例1-2)。 圖8係相對於水添加後之胺基矽烷化合物之濃度之表面處理後之接觸角之圖表(比較例1-1、比較例1-2、實施例1-3、實施例1-2、實施例1-1)。 圖9係相對於iPA添加量之表面處理後之接觸角之圖表(比較例1-1、實施例1-6、實施例1-5、實施例1-4、比較例1-3)。 圖10係相對於iPA添加後之胺基矽烷化合物之濃度之表面處理後之接觸角之圖表(比較例1-1、比較例1-3、實施例1-6、實施例1-5、實施例1-4)。Figure 1 is a flow chart of surface treatment mode 1. Figure 2 is a flow chart of the surface treatment mode 2. Figure 3 is a flowchart of the surface treatment mode 3. FIG. 4 is a flowchart of surface treatment mode 4. Figure 5 is a flowchart of the surface treatment mode 5. FIG. 6 is a flowchart of the surface treatment mode 6. Fig. 7 is a graph of contact angle after surface treatment with respect to the amount of water added (Comparative Example 1-1, Example 1-3, Example 1-2, Example 1-1, Comparative Example 1-2). Figure 8 is a graph of the contact angle after surface treatment relative to the concentration of the aminosilane compound after water addition (Comparative Example 1-1, Comparative Example 1-2, Example 1-3, Example 1-2, Implementation Example 1-1). Fig. 9 is a graph of the contact angle after surface treatment relative to the amount of iPA added (Comparative Example 1-1, Example 1-6, Example 1-5, Example 1-4, Comparative Example 1-3). Figure 10 is a graph of the contact angle after surface treatment relative to the concentration of the aminosilane compound after iPA addition (Comparative Example 1-1, Comparative Example 1-3, Example 1-6, Example 1-5, Implementation Example 1-4).

Claims (19)

一種撥水性保護膜形成用藥液,其具有 (I)下述通式[1]所表示之胺基矽烷化合物、 (II)下述通式[2]所表示之矽化合物、及 (III)非質子性溶劑,且 相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%,
Figure 03_image043
[式[1]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;a係1~3之整數,b係0~2之整數,且a與b合計為1~3],
Figure 03_image045
[式[2]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;又,X表示鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 所組成之群中之至少1種基;R3 係碳數為1至6之1價全氟烷基,c係1~3之整數,d係0~2之整數,且c與d合計為1~3]。
A chemical solution for forming a water-repellent protective film, comprising (I) an aminosilane compound represented by the following general formula [1], (II) a silicon compound represented by the following general formula [2], and (III) Protic solvent, and the content of (I) relative to the total amount of (I) to (III) is 0.02 to 0.5% by mass,
Figure 03_image043
[In formula [1], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; a is an integer of 1 to 3, b is an integer of 0-2, and the total of a and b is 1-3],
Figure 03_image045
[In the formula [2], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon numbers from 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; and X represents a halogen group,- OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C(S(=O) 2 -R 3 ) 3 At least one group in the group; R 3 is a monovalent perfluoroalkyl group with carbon number of 1 to 6, c is an integer of 1 to 3, d is an integer of 0 to 2, and the total of c and d is 1 to 3].
如請求項1之撥水性保護膜形成用藥液,其中上述(I)為下述通式[3]所表示之化合物,
Figure 03_image047
[式[3]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。
The chemical solution for forming a water-repellent protective film according to claim 1, wherein the above (I) is a compound represented by the following general formula [3],
Figure 03_image047
[In formula [3], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].
如請求項1之撥水性保護膜形成用藥液,其進而含有(IV)下述通式[4]所表示之矽氮烷化合物,
Figure 03_image049
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。
The chemical solution for forming a water-repellent protective film of claim 1, which further contains (IV) a silazane compound represented by the following general formula [4],
Figure 03_image049
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].
如請求項1之撥水性保護膜形成用藥液,其中相對於上述(I)~(III)之總量之(II)之含量為0.05~20質量%。The water-repellent protective film forming chemical solution of claim 1, wherein the content of (II) relative to the total amount of (I) to (III) above is 0.05-20% by mass. 如請求項1之撥水性保護膜形成用藥液,其中上述(II)為下述通式[5]所組成之群中之至少1種化合物,
Figure 03_image051
[式[5]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基,R3 係碳數為1至6之1價全氟烷基;又,g係1~3之整數]。
The chemical solution for forming a water-repellent protective film according to claim 1, wherein the above (II) is at least one compound in the group consisting of the following general formula [5],
Figure 03_image051
[In formula [5], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with a carbon number of 1 to 18 that can be substituted with a part or all of hydrogen elements and fluorine elements, and R 3 is a monovalent organic group with a carbon number of 1 to 6 is a monovalent perfluoroalkyl group; and, g is an integer of 1 to 3].
一種晶圓之表面處理方法,其具有撥水性保護膜形成步驟、及乾燥步驟,該撥水性保護膜形成步驟係於晶圓表面保持有選自由洗淨液及沖洗液所組成之群中之至少1種液體之狀態下,將該液體替換為撥水性保護膜形成用藥液且將該藥液保持於晶圓表面, 上述撥水性保護膜形成用藥液具有 (I)下述通式[1]所表示之胺基矽烷化合物、 (II)下述通式[2]所表示之矽化合物、及 (III)非質子性溶劑,且 相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%,
Figure 03_image053
[式[1]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;a係1~3之整數,b係0~2之整數,a與b合計為1~3],
Figure 03_image055
[式[2]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;又,X表示鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 所組成之群中之至少1種基;R3 係碳數為1至6之1價全氟烷基,c係1~3之整數,d係0~2之整數,且c與d合計為1~3]。
A method for surface treatment of a wafer, which has a water-repellent protective film forming step and a drying step. The water-repellent protective film forming step maintains at least one selected from the group consisting of a cleaning solution and a rinse solution on the surface of the wafer In the state of one liquid, replace the liquid with a chemical solution for forming a water-repellent protective film and hold the chemical solution on the wafer surface. The chemical solution for forming a water-repellent protective film has (I) the following general formula [1] (II) the silicon compound represented by the following general formula [2], and (III) aprotic solvent, and relative to the total amount of (I) to (III) (I) The content is 0.02~0.5% by mass,
Figure 03_image053
[In formula [1], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; a is an integer of 1 to 3, b is an integer of 0-2, and the total of a and b is 1-3],
Figure 03_image055
[In the formula [2], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon numbers from 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; and X represents a halogen group,- OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C(S(=O) 2 -R 3 ) 3 At least one group in the group; R 3 is a monovalent perfluoroalkyl group with carbon number of 1 to 6, c is an integer of 1 to 3, d is an integer of 0 to 2, and the total of c and d is 1 to 3].
如請求項6之晶圓之表面處理方法,其中上述(I)為下述通式[3]所表示之化合物,
Figure 03_image057
[式[3]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。
The surface treatment method of a wafer according to claim 6, wherein the above (I) is a compound represented by the following general formula [3],
Figure 03_image057
[In formula [3], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with a part or all of hydrogen elements, which can be substituted with fluorine; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].
如請求項6之晶圓之表面處理方法,其中上述撥水性保護膜形成用藥液進而含有(IV)下述通式[4]所表示之矽氮烷化合物,
Figure 03_image059
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。
The method for surface treatment of a wafer according to claim 6, wherein the chemical solution for forming a water-repellent protective film further contains (IV) a silazane compound represented by the following general formula [4],
Figure 03_image059
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].
如請求項6之晶圓之表面處理方法,其於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使質子性化合物與具有 (II)上述通式[2]所表示之矽化合物、 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(III)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液,
Figure 03_image061
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。
Such as the surface treatment method of the wafer of claim 6, which has a chemical solution preparation step before the water-repellent protective film forming step, and the chemical solution preparation step is to combine the protic compound with the formula (II) described in [2] above The silicon compound represented by (IV) the silazane compound represented by the following general formula [4], and (III) the raw material drug solution of the aprotic solvent are compared with the ratio of (II), (III), (IV) The total amount of 1 kg is contacted at the ratio of 0.001 to 0.3 mol, thereby preparing the preparation having the above (I) to (III) and the content of (I) relative to the total amount of (I) to (III) is 0.02 to 0.5 The mass% of the water-repellent protective film forming liquid,
Figure 03_image061
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].
如請求項8之晶圓之表面處理方法,其於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使質子性化合物與具有 (II)上述通式[2]所表示之矽化合物、 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(II)、(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液,
Figure 03_image063
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3]。
Such as the surface treatment method of the wafer of claim 8, which has a chemical solution preparation step before the water-repellent protective film formation step, and the chemical solution preparation step is to combine the protic compound with the formula (II) described above in [2] The silicon compound represented by (IV) the silazane compound represented by the following general formula [4], and (III) the raw material drug solution of the aprotic solvent are compared with the ratio of (II), (III), (IV) The total amount of 1 kg is contacted at a ratio of 0.001 to 0.3 mol, whereby the preparation has the above (I) to (IV) and the content of (I) relative to the total amount of (I) to (III) is 0.02 to 0.5 The mass% of the water-repellent protective film forming liquid,
Figure 03_image063
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer of 0-2, and the total of e and f is 3].
如請求項9或10之晶圓之表面處理方法,其中上述藥液製備步驟係將上述原料藥液導入至含有質子性化合物之空間中而使兩者接觸。The method for surface treatment of wafers according to claim 9 or 10, wherein the liquid chemical preparation step is to introduce the raw chemical liquid into the space containing the protic compound to bring the two into contact. 如請求項9或10之晶圓之表面處理方法,其中上述質子性化合物為氣體狀態。According to claim 9 or 10, the surface treatment method of a wafer, wherein the protic compound is in a gas state. 如請求項9或10之晶圓之表面處理方法,其中上述質子性化合物為液體狀態。According to claim 9 or 10, the wafer surface treatment method, wherein the protic compound is in a liquid state. 如請求項9或10之晶圓之表面處理方法,其中上述質子性化合物為具有-OH基、及/或-NH2 基之化合物。According to claim 9 or 10, the surface treatment method of a wafer, wherein the protic compound is a compound having an -OH group and/or a -NH 2 group. 如請求項9或10之晶圓之表面處理方法,其中上述質子性化合物為水、及/或2-丙醇。According to claim 9 or 10, the surface treatment method of a wafer, wherein the protic compound is water and/or 2-propanol. 如請求項6之晶圓之表面處理方法,其於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使下述通式[6]所表示之酸性化合物與具有 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(III)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液,
Figure 03_image065
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3],
Figure 03_image067
[式[6]中,X表示鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 ;R3 係碳數為1至6之1價全氟烷基]。
The surface treatment method of a wafer according to claim 6, which has a chemical solution preparation step before the water-repellent protective film formation step, and the chemical solution preparation step is to make the acidic compound represented by the following general formula [6] and have ( IV) The silazane compound represented by the following general formula [4] and the raw material liquid medicine of (III) aprotic solvent are 0.001-0.3 mol relative to the total 1 kg of (III) and (IV) To prepare a water-repellent protective film forming chemical solution having the above (I) to (III) and the content of (I) relative to the total amount of (I) to (III) of 0.02 to 0.5% by mass. ,
Figure 03_image065
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer from 0 to 2, and the total of e and f is 3],
Figure 03_image067
[In formula [6], X represents a halogen group, -OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C( S(=O) 2 -R 3 ) 3 ; R 3 is a monovalent perfluoroalkyl group having 1 to 6 carbon atoms].
如請求項8之晶圓之表面處理方法,其於上述撥水性保護膜形成步驟之前具有藥液製備步驟,該藥液製備步驟係使下述通式[6]所表示之酸性化合物與具有 (IV)下述通式[4]所表示之矽氮烷化合物、及 (III)非質子性溶劑之原料藥液 以相對於(III)、(IV)之總量1 kg為0.001~0.3莫耳之比率進行接觸,藉此 製備具有上述(I)~(IV)且相對於(I)~(III)之總量之(I)之含量為0.02~0.5質量%之撥水性保護膜形成用藥液,
Figure 03_image069
[式[4]中,R1 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基;e係1~3之整數,f係0~2之整數,且e與f合計為3],
Figure 03_image071
[式[6]中,X表示鹵基、-OC(=O)R3 、-OS(=O)2 -R3 、-N(S(=O)2 -R3 )2 、-C(S(=O)2 -R3 )3 ;R3 係碳數為1至6之1價全氟烷基]。
The surface treatment method of a wafer according to claim 8, which has a chemical solution preparation step before the water-repellent protective film formation step, and the chemical solution preparation step is to make the acidic compound represented by the following general formula [6] and have ( IV) The silazane compound represented by the following general formula [4] and the raw material liquid medicine of (III) aprotic solvent are 0.001-0.3 mol relative to the total 1 kg of (III) and (IV) To prepare a water-repellent protective film forming chemical solution having the above (I) to (IV) and the content of (I) relative to the total amount of (I) to (III) of 0.02 to 0.5% by mass. ,
Figure 03_image069
[In formula [4], R 1 is each independently a monovalent organic group containing a monovalent hydrocarbon group with carbon number 1 to 18, which can be substituted with fluorine, part or all of the hydrogen elements; e is an integer of 1 to 3, f is an integer from 0 to 2, and the total of e and f is 3],
Figure 03_image071
[In formula [6], X represents a halogen group, -OC(=O)R 3 , -OS(=O) 2 -R 3 , -N(S(=O) 2 -R 3 ) 2 , -C( S(=O) 2 -R 3 ) 3 ; R 3 is a monovalent perfluoroalkyl group having 1 to 6 carbon atoms].
如請求項6之晶圓之表面處理方法,其中相對於上述(I)~(III)之總量之(II)之含量為0.05~20質量%。Such as claim 6, wherein the content of (II) relative to the total amount of (I) to (III) above is 0.05-20% by mass. 如請求項6之晶圓之表面處理方法,其中上述(II)為下述通式[5]所組成之群中之至少1種化合物,
Figure 03_image073
[式[5]中,R2 分別相互獨立地為包含部分或全部氫元素可取代為氟元素之碳數為1至18之1價烴基之1價有機基,R3 係碳數為1至6之1價全氟烷基;又,g係1~3之整數]。
The surface treatment method of wafer according to claim 6, wherein the above (II) is at least one compound in the group consisting of the following general formula [5],
Figure 03_image073
[In formula [5], R 2 is each independently a monovalent organic group containing a monovalent hydrocarbon group with a carbon number of 1 to 18 that can be substituted with a part or all of hydrogen elements and fluorine elements, and R 3 is a monovalent organic group with a carbon number of 1 to 6 is a monovalent perfluoroalkyl group; and, g is an integer of 1 to 3].
TW108101088A 2018-01-15 2019-01-11 Chemical solution for forming water-repellent protective film and wafer surface treatment method TWI707030B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018003977 2018-01-15
JP2018-003977 2018-01-15
JP2018-231703 2018-12-11
JP2018231703A JP7277700B2 (en) 2018-01-15 2018-12-11 Chemical solution for forming water-repellent protective film and method for surface treatment of wafer

Publications (2)

Publication Number Publication Date
TW201932575A TW201932575A (en) 2019-08-16
TWI707030B true TWI707030B (en) 2020-10-11

Family

ID=67398155

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108101088A TWI707030B (en) 2018-01-15 2019-01-11 Chemical solution for forming water-repellent protective film and wafer surface treatment method

Country Status (5)

Country Link
JP (1) JP7277700B2 (en)
KR (1) KR102465276B1 (en)
CN (1) CN111630633B (en)
SG (1) SG11202005846XA (en)
TW (1) TWI707030B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115110094A (en) * 2021-03-18 2022-09-27 江苏筑磊电子科技有限公司 Method for treating metal surface of dipropylene glycol after fire
WO2023199824A1 (en) * 2022-04-11 2023-10-19 セントラル硝子株式会社 Surface treatment composition and method for producing wafer
WO2024070526A1 (en) * 2022-09-30 2024-04-04 富士フイルム株式会社 Chemical solution, method for producing modified substrate, and method for producing layered body

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200302259A (en) * 2001-11-15 2003-08-01 Honeywell Int Inc Spin-on-glass anti-reflective coatings for photolithography
JP2012015335A (en) * 2010-06-30 2012-01-19 Central Glass Co Ltd Chemical for forming protective film, and cleaning method of wafer surface

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821844B2 (en) 1975-04-03 1983-05-04 日本電気株式会社 micro hatadan filter
US9228120B2 (en) * 2010-06-07 2016-01-05 Central Glass Company, Limited Liquid chemical for forming protecting film
WO2011155407A1 (en) * 2010-06-07 2011-12-15 セントラル硝子株式会社 Chemical solution for formation of protective film
WO2012002200A1 (en) * 2010-06-30 2012-01-05 セントラル硝子株式会社 Wafer cleaning method
JP2013118347A (en) 2010-12-28 2013-06-13 Central Glass Co Ltd Cleaning method of wafer
JP2013104954A (en) * 2011-11-11 2013-05-30 Central Glass Co Ltd Wafer surface treatment method and surface treatment liquid
JP2017168828A (en) * 2016-03-15 2017-09-21 セントラル硝子株式会社 Chemical solution for water-repellent protection film formation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200302259A (en) * 2001-11-15 2003-08-01 Honeywell Int Inc Spin-on-glass anti-reflective coatings for photolithography
JP2012015335A (en) * 2010-06-30 2012-01-19 Central Glass Co Ltd Chemical for forming protective film, and cleaning method of wafer surface

Also Published As

Publication number Publication date
JP2019123860A (en) 2019-07-25
CN111630633B (en) 2023-09-19
SG11202005846XA (en) 2020-07-29
CN111630633A (en) 2020-09-04
JP7277700B2 (en) 2023-05-19
TW201932575A (en) 2019-08-16
KR20200108887A (en) 2020-09-21
KR102465276B1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US8828144B2 (en) Process for cleaning wafers
KR101363441B1 (en) Chemical solution for formation of protective film, process for preparing thereof and process for cleaning using the same
WO2012090779A1 (en) Wafer washing method
US9748092B2 (en) Liquid chemical for forming protecting film
TWI707030B (en) Chemical solution for forming water-repellent protective film and wafer surface treatment method
US20170062203A1 (en) Method of Preparing Liquid Chemical for Forming Protective Film
WO2012002145A1 (en) Chemical solution for forming water-repellent protective film
US20120164818A1 (en) Process for Cleaning Wafers
JP2013104954A (en) Wafer surface treatment method and surface treatment liquid
JP5716527B2 (en) Chemical solution for forming water repellent protective film and method for cleaning wafer using the chemical solution
KR102509450B1 (en) Manufacturing method of surface treatment agent and surface treatment body
US11282709B2 (en) Chemical agent for forming water repellent protective film and surface treatment method for wafers
KR101680438B1 (en) Wafer surface-treatment method and surface-treatment liquid, and surface-treatment agent, surface-treatment liquid, and surface-treatment method for silicon-nitride-containing wafers
TWI704153B (en) Water-repellent protective film forming agent, chemical liquid for forming water-repellent protective film, and surface treatment method of wafer
TWI692675B (en) Medicine liquid for forming water-repellent protective film, preparation method thereof, and method for manufacturing surface treatment body
JP5953707B2 (en) Surface treatment agent for silicon nitride containing wafer, surface treatment liquid, and surface treatment method
JP6098741B2 (en) Wafer cleaning method
TW202111077A (en) Surface treatment agent and method for manufacturing surface treatment body
JP2012178432A (en) Water-repellent protective film forming solution